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ABSTRACT
The ??????????????????????????????????????????????????????????????? ?????
pathological hallmark of Alzheimer’s disease (AD), which is most notably characterized 
by synaptic dysfunction. Strategies targeting heat shock protein 90 (Hsp90) inhibition 
have been widely investigated in the treatment of cancer for over two decades. Its 
application in the treatment of neurodegenerative diseases however, has emerged more 
recently in the last decade. The role of the Hsp90 chaperone in clearing misfolded protein 
aggregates has been well established (in vitro only), but its function in synaptic activity 
remains elusive. 
In our study, we utilized a widely used Hsp90 inhibitor, 17-AAG (17-allylamino-
17-desmethoxygeldanamycin), to show that 17-AAG not only induces a heat shock-like 
response, but also regulates (likely at the transcriptional level as modeled by qRT-PCR) 
select proteins enriched in the synapse, such as Post-synaptic density 95 (PSD95), 
synapsin I, and brain-derived neurotrophic factor (BDNF), among others. Confocal 
imaging demonstrated rescued dendritic spines with 17-???????????????????????
challenge in neuronal culture models. The functionality of these changes in the synapse 
was further confirmed by memory improvement in contextual fear conditioning tests. 
This work implied a potential strategy in using Hsp90 inhibitors to treat AD. 
Nevertheless, it must be noted that 17-AAG has limited feasibility in therapy due to its 
poor CNS-permeability.
In order to test the hypothesis inspired and encouraged by the initial 17-AAG
experimental results, we instead used a similar compound with favorable CNS-
permeability. OS47720, a radicicol derivative Hsp90 inhibitor, produced comparable 
effects to those of 17-AAG in inducing heat shock-like responses and promoting synaptic 
protein expression. Electrophysiology studies on coherence demonstrated enhancement 
of neuronal activity within the cortical hippocampal network. Most importantly, chronic 
0S47720 administration for three months and six months in early and middle 
symptomatic AD mouse model (Tg2576) both rescued memory deficits without obvious 
systemic toxicity. OS47720, as an Hsp90 inhibitor, was the first reported compound to 
display therapeutic effects after long-term treatment in an AD animal model. Post-
mortem studies revealed elevation in protein expression of heat shock proteins, synaptic 
??????????????????????????????????????????????????????????????????????
neuroinflammation. Downregulation of heat shock factor 1 (HSF1) by either a 
pharmacological inhibitor or a virus-delivered shRNA abolished OS47720’s effects on 
???????????????????????????????????????????????????????????????????????????????
memory. Together with the notion that HSF1-regulated BDNF mRNA, this implicated an 
HSF1-mediated mechanism at the transcriptional level of synaptic genes. Importantly, 
these observable effects bypassed several important signaling pathways, including the 
survival Protein kinase B (PKB or AKT) pathway which is an underlying mechanism of 
most neuroprotective drugs.
v
These findings revealed a novel function of Hsp90 inhibition in regulating
synaptic gene expression and synaptic activity, further supporting the potential of using 
Hsp90 inhibitors in treating neurodegenerative diseases such as AD.
vi
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CHAPTER 1.   LITERATURE REVIEW AND HYPOTHESIS
1.1 Neurodegenerative Diseases
1.1.1 Neurodegenerative Diseases
Neurodegeneration is an umbrella term describing neurodegenerative processes 
involving progressive loss of both structure and function in affected brain cells, which are 
primarily neurons. Neurodegenerative diseases are various types of brain diseases caused 
by neurodegeneration, the four most common of which include Alzheimer's disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis 
(ALS). Other less prevalent but similar diseases include Corticobasal degeneration
(CBD), Progressive supranuclear palsy (PSP), Dementia with Lewy Bodies (DLB), 
Frontotemporal dementia (FTD), Frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17), Multiple system atrophy (MSA), Spinobulbar muscular 
atrophy (SBMA), and Spinocerebellar ataxia (SCA). Each of these diseases is believed to 
be irreversible and incurable, resulting in progressive deterioration of neuronal cells that 
eventually leads to death. 
Neurodegeneration has two major types of consequences. The first is problematic 
mental functioning (dementia), while the other is the impaired movement (ataxia). 
Symptoms of each disease vary from person to person. Mental dysfunction is the most 
prominent symptom of AD. Common symptoms of AD include progressive memory loss 
and confusion, difficulty in learning new things, problems with mood control, and trouble 
with language. PD, HD and ALS are also mainly characterized by movement problems. 
Symptoms of PD patients include slowed and limited movement, rigid and aching
muscles (including throat muscles), and difficulty with walking and balance. HD patients 
experience memory loss, problems with decision-making and mood swings (depression, 
anger, etc.) in early stages. Later on, the following symptoms appear: involuntary 
twitching or other uncontrolled movements, rigid muscle, muscle contracture, difficulty 
in walking, abnormal eye movement, and difficulty with speaking and/or swallowing. PD 
and HD also demonstrate mental changes in the late stages of the disease that confer 
cognitive decline. ALS is mainly characterized as a movement disorder. ALS patients 
have progressive muscle weakness from disease onset, leading to unfortunate actions 
such as tripping, dropping things, and muscle cramps. When ALS worsens, the affected 
individual may lose voluntary control of basic actions such as laughing or crying, and 
more seriously may lose control of life-dependent actions such as breathing, necessitating 
permanent use of external ventillatory support (NINDS, 2013).
1.1.2 Risk Factors
Several risk factors have been linked to neurodegenerative diseases, the two most 
prominent of which are age and family history (genetic predisposition). Other risk factors 
1
include oxidative stress, inflammation, infection, stroke, hypertension, diabetes, head 
trauma, tumors, depression, smoking, vitamin deficiencies, race, gender, endocrine 
conditions, immune and metabolic conditions, chemical exposure and even level of 
education (Brown et al., 2005). 
In AD, age is the biggest risk factor. According to prevalence reports in 2013, AD 
prevalence rates were 0.28% in the population of 65-69 years old. This number rose to 
5.6% in individuals 90 years old and older population. About 4% of AD patients are less
than 65 years old. 15% of patients are 65-74 years old and 81% of patients are 75 years 
old or older (Hebert et al., 2013). Age is also the greatest risk factor in PD (Hindle et al., 
2010). A meta-analysis showed an increasing prevalence of PD with age worldwide, from 
107 per 100,000 patients in 50-59 years to 1903 per 100,000 patients in 80 years old and 
above (Pringsheim et al., 2014). Aging not only increases the probability of getting 
neurodegeneration, but also impairs neuronal self-repair. For instance, loss or restricted 
neurogenesis in the hippocampus, subventricular zone (SVZ)/rostral migratory stream 
(RMS) and olfactory epithelium (OE) was observed in the aging brain (Riddle and 
Lichtenwalner, 2007; Shetty et al., 2011). 
Genetic predisposition represents another main risk factor for many types of 
neurodegenerative diseases, such as early-onset familial AD (eFAD or FAD), late onset 
AD (LOAD), familial early-onset Parkinsonism, HD, and Familial ALS (FALS). Though 
eFAD accounts for only a small percent of all AD cases (less than 5%), it typically 
appears at an earlier age (less than 65 years), featuring genetic autosomal dominant 
inheritance within affected families (Bertram and Tanzi, 2005). Currently three different 
genes with over 160 mutations have been found to cause eFAD. These genes include the 
amyloid precursor protein on chromosome 21 (APP), presenilin 1 (PSEN1) on 
chromosome 14, and presenilin 2 (PSEN2) on chromosome 1 (Zhang et al., 1998). 
Among them, PSEN1 is the most common mutated gene which accounts for most AD 
cases with early disease onset before 50 years old. In contrast, LOAD mainly affects 
people aged over 65 years old and represents the majority of all AD cases. The gene most 
associated with LOAD is apolipoprotein E (APOE), which is located on chromosome 
??????????????????? ???????????????????????????????????????????????????????????????????
most common polymorphisms found in all populations (Strittmatter et al., 1993; 
Schmechel et al., 1993).  Though the impact of genetic factors contributing to overall 
prevalence of PD is less significant than in AD, there are still more than 5 genes that have 
been reported to cause familial early-????????????????????????????????????????????-
synuclein; PRKN or PARK2: parkin; DJ1 or PARK7: DJ-1; PINK1 or PARK6: PTEN-
induced putative kinase I; LRRK2 or PARK8: leucine-rich repeat kinase 2, also known as 
dardarin) (Bertram et al., 2005). Familial ALS (FALS) comprises about 10% of all ALS 
cases, but that is not indicative of the overall influence genetic factors play in ALS. 
Several genes have been implicated with ALS development, including SOD1, TDP-43, 
MAPT, and ALS2. In contrast to these diseases affected by aging and multiple genetic 
mutations, HD is found to be solely hereditary and affected by a single gene, huntingtin 
(HTT) (Kremer et al., 1994). 
2
In addition to age-related and genetic factors, there are also other influences that 
have been known to be associated with neurodegenerative diseases. For instance, 
oxidative stress is a well-studied phenomenon that leads to free radical attack on neuronal 
cells. Imbalanced oxygen metabolism and excessive reactive oxygen species (ROS) in the 
brain are implicated in most neurodegenerative diseases (AD, PD, HD, ALS, etc.) (Uttara 
et al., 2009; Shukla et al., 2011). Neuroinflammation induced by systemic infection and 
activation of the innate immune response in the brain is mainly mediated by astrocyte and 
microglia, the key components of innate immune cells in the central nervous system 
(CNS). Increased neuroinflammation triggers neurotoxic pathways that cause progressive 
degeneration of neuronal cells (Perry et al., 2003; Amor et al., 2010; Amor et al., 2014). 
Besides these two most studied factors, there are also other contributing factors. A meta-
analysis shows HD prevalence varied by races (Pringsheim et al., 2012) indicating 
existence of race factor. All these factors together with other potential or unknown factors 
lead to the occurrence of neurodegenerative diseases.  
1.1.3 Protein Misfolding and Aggregation in Neurodegeneration
Though each disease has its own set of symptoms and associations with different 
gene mutations, there exists a common molecular pathway that has been implicated in 
various neurodegenerative diseases, which includes protein misfolding, accumulation and 
aggregation. It has been well established that accumulation and aggregation of misfolded 
proteins leads to synaptic alternation, neuronal damage, cell death, brain dysfunction, and 
disease (Soto and Estrada, 2008). 
There are two histopathological hallmarks of AD: extracellularly localized senile 
plaques (also known as Alzheimer’s plaques, neuritic plaques or amyloid plaques) and 
intracellularly localized neurofibrillary tangles (NFT), affecting brain regions including 
the hippocampus, cortex, basal forebrain, brain stem, and cerebellum. AD has been 
recognized as a protein misfolding disease because of the abnormal accumulation of 
misfolded Amyloid-?????????????????????????-?????????????????????????????????????????
AD and Down’s syndrome patients and was identified to be the main component of the 
????????????????????????????? ?????????????????????????????????????????????????
precursor, Amyloid Precursor Protein (APP). APP has a transmembrane fragment 
structure that can be cleaved at the N-??????????????????????????? ???????-associated 
beta-???????????????????????????????????????????????????-secretase) between Met671 and 
???????????????????????????????????????????????????????????????????????????????????
????????????? ???????-associated C-te??????????????????????????????????????????
???????????????????????????????-????????????????????????????????????????????????????????
intracellular domain (AICD) (Gandy, 2005) (Figure 1-1). The PSEN1 protein coded by 
?????????????????????????????-secretase com?????? ????????????????????????????????????
???-???????????? ???????????????????? ???????????????????-42 (less than 5%) (Naslund 
?????????????????????? ??????????????????????????????????????????????????????????????????????
not fully understood (Hiultunen et al., 2009). Several studies revealed potential functions 
?????????? ???????????? ??????????????????????????????????????????????????????????????
activation, and proinflammatory activity (Baruch-Suchodolsky and Fischer., 2009; 
3
Figure 1-1 APP P?????????????????Accumulation.
Reprinted with permission. Gandy S. (2005) The role of cerebral amyloid beta 
accumulation in common forms of Alzheimer disease. J Clin Invest. 115, 1121-1129.
The cartoon illustrates the A???????????????????????????????????????????????????????
plaques. APP has a transmembrane fragment structure which can be cleaved at the N-
??????????????????????????? ???????-associated beta-site amyloid precursor protein 
????????????????????-secretase) between Met671 and Asp672. This cleavage process 
?????????????????????????????????????????????????????????????????? ???????-associated 
C-???????????????????????????????????????????????????????????????????????????-
??????????????????????????????????????????????? APP intracellular domain (AICD). APP 
?????????????????????????????????-????????????????????????????????????????????????????????
?????????????? ???????-????????????????????????????????????????????????????????????
cause synapse impairment, neuronal death, cognitive and behavioral abnormalities. Senile 
plaques are formed after consid???????????????????.
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Tabaton et al., 2010; Soscia et al., 2010). Some studies show participation of monomeric 
?????? ????????????????????????????????????????????????? ????????????quired for 
synaptic plasticity and survival of neurons (Parihar and Brewer, 2010). Misfolding of the 
???????????????????????????????????????????????? ??????????????????????????????????
trimers, tetramers, and oligomers. Eventually senile plaques are formed by further 
?????????????????????????????????????????????????????????????????????????-secretase 
between Lys687 and Leu688, resulting in generation of a membrane-bound fragment 
named C-?????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????-
toxic species and promotes growth of neurons before and after birth (Levites et al., 2003; 
??????????????????????????????????????????????????????? ??????????????????????????
agg???????????????????? ???????????????????????????? ???????????????????????? ????
potent toxic species for all neuronal cells, promoting neurodegeneration by perturbing 
normal function of many subcellular organelles such as the mitochondria and 
endoplasmic reticulum (Mattson et al., 2001; Hashimoto et al., 2003; Pagani and Eckert, 
2011). This series of events eventually causes neuronal cell death, and cognitive and 
behavioral abnormalities (Gandy, 2005; Sakano and Zako, 2010). AD is also recognized 
as a tauopathy due to the abnormally aggregated misfolded and hyperphosphorylated tau 
protein. Tau protein belongs to a group of cytoskeletal component proteins referred to as 
microtubule-associated proteins (MAP),  which are abundantly expressed in neurons that 
bind to and stabilize microtubules. Conformational changes, hyperphosphorylation and 
misfoldings of tau lead to aberrant aggregations where paired helical filaments (PHF) of 
tau are formed, further aggregation leading to form the other hallmark of AD, 
neurofibrillary tangles. The extent of the tau aggregation correlates with intensity of cell 
death and cognitive dysfunction (Iqbal et al., 2005). Tauopathy can also be seen in other 
neurodegenerative diseases such as Down’s syndrome, Frontotemporal dementia (FTD),
and Cortico-basal degeneration (CBD).
The pathological characteristics of PD are the progressive accumulation of 
???????????-synuclein filaments and their aggregation in the form of Lewy bodies and 
Lewy neurites. A Lewy body is an inclusion body in the cytoplasm consisting of 
????????????-synuclein protein and Lewy neurites contain granular material and 
??????????-synuclein filaments (Dauer and Przedborski, 2003; Ross and Poirier, 2004). 
???????????????????????????????-synuclein can be found in brain regions of diseased 
patients including the basal ganglia, sustantia nigra, and cortex. 
HD is caused by a mutation in the HTT gene that abnormally expands an 
increased number of cytosine-adenine-guanine (CAG) nucleotide repeats, which leads to 
expression of the huntingtin (HTT) protein with an abnormally high number of glutamine 
(polyQ) repeats. The expansion of polyQ promotes misfolding and aggregation to form 
the disease-causing pathological hallmark of HD, intracellular aggregates of mutant Htt 
called inclusion bodies and intranuclear inclusions, which are usually located in the 
striatum, cortex, and basal ganglia regions. The formation of an inclusion body was found 
to be beneficial in HD by reducing levels of the toxic species of misfolded HTT protein 
from diffuse fraction. (The Huntington's Disease Collaborative Research Group, 1993; 
Arrasate and Finkbeiner, 2012). In familial amyotrophic lateral sclerosis (fALS), 
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mutations in superoxide dismutase 1 (SOD1) are a causal factor to induce misfolding and 
aggregation of the SOD1 protein to form various types of inclusions in spinal motor 
neurons and the motor cortex (Prudencio and Borchelt, 2011). These inclusions include 
Lewy-body-like hyaline inclusions (LBHIs), hyaline conglomerate inclusions (HCIs), 
skein-like inclusions, Bunina bodies, and axonal spheroids (Kerman and Chakrabartty, 
2011). These four major neurodegenerative diseases with disease-causing proteins are 
summarized in Table 1-1.
Protein misfolding and aggregation are also commonly found in other 
neurodegenerative diseases, such as misfolded and aggregated ataxin protein in 
spinocerebellar ataxia (SCA), misfolded androgen receptor (AR) in spinal bulbar 
muscular atrophy (SBMA), mutated/hyperphosphorylated tau misfolded protein in 
frontotemporal dementia (FTD), etc. This common molecular pathway has emerged as 
the mechanism of toxicity to neuronal cells and warrants further investigation into 
potential therapeutic approaches. 
1.1.4 Alzheimer’s Disease
Alzheimer’s disease (AD) is currently the 6th leading overall cause of death 
overall, and the 5th leading cause of death for those over 65 years of age in the United 
States. It is the most common neurodegenerative disease, and is also the most common 
irreversible cause of dementia accounting for over 60% of all dementia cases (Wilson et 
al., 2012). Clinical signs of AD are mainly characterized by progressive deterioration and 
reduced activity of daily functioning abilities, along with neuropsychiatric symptoms and 
abnormal changes of behavior. In 2015, 5.3 million Americans were living with AD, a 
number that is projected to increase to 16 million by 2050. According to the Alzheimer’s 
Association annual report, the direct cost burden of AD to American society to care for 
those who have AD is at USD $226 billion for 2015, and according to one model, unless 
something is done, this cost will increase to $1.1 trillion (in 2015 dollars). Unfortunately, 
there is no cure for AD and “AD is currently the only cause of death among the top 10 in 
the United States that cannot be prevented, cured, or even slowed” (Alzheimer’s 
association, 2015).
AD affects people in different ways. The most common symptom in the initial 
stages is a gradual loss of ability to remember new things. This is because the first brain 
cells to degenerate are neurons localized in specific brain regions (for example 
hippocampus and cerebral cortex) that are involved in forming new memories. When 
degeneration spreads to neurons in other parts of the brain, individuals will experience 
more difficulties in daily life, including loss of memory, cognitive and language skills, 
and behavior changes. The brain will eventually shrink as a result of AD-induced tissue 
loss.
To date, there are five medications approved by the U.S. Food and Drug 
Administration (FDA) to treat the symptoms of AD. They are limited to 
acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and rivastigmine) and N-
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Table 1-1 Disease Proteins and Pathology in Major Neurodegenerative Disease.
Disease
Associated 
genes
Major protein 
deposited
Characteristic 
pathology
Brain regions 
affected
Alzheimer’s 
disease (AD)
APP, PSEN1, 
PSEN2, MAPT
?????
hyperphospho-
rylated tau
Neuritic 
plaques and 
neurofibrillary 
tangles
Hippocampus, 
cortex, basal 
forebrain, 
brain stem, 
cerebellum
Parkinson’s 
disease (PD)
SNCA, DJ1, 
PINK1, PARK, 
LRRK2,etc.
?-synuclein Lewy bodies 
and Lewy 
neurites
Basal ganglia, 
Sustantia 
nigra, cortex
Huntington’s 
disease (HD)
HTT Huntingtin Neuronal 
inclusion body 
and 
Intranuclear 
inclusions
Striatum, other 
basal ganglia, 
cortex
Amyotrophic 
lateral 
sclerosis 
(ALS)
SOD1, TDP-43,
MAPT, etc
SOD1 Lewy-body-
like hyaline 
inclusions, 
Bonia bodies, 
axonal 
spheroids, etc.
Spinal motor 
neurons and 
motor cortex
Notes: Modified with permission. Ross CA, Poirier MA. (2004). Protein aggregation and 
neurodegenerative disease. Nat Med. 10, S10-17.
Disease proteins and associated genes in four major neurodegenerative diseases, together 
with characteristic pathology and affected brain regions. (modified from Ross and Poirier 
et al., 2004).
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methyl-D-aspartate (NMDA) receptor antagonists (memantine), or a combination of these 
agents (donepezil and memantine). Current drugs are dedicated to ameliorate AD 
symptoms rather than treat the disease itself or delay its progression. Therefore, a 
breakthrough in research & development (R&D) of AD drugs is urgently needed.
1.1.5 Alzheimer’s Disease: Synapse Disease
It has been almost a century since Dr. Santiago Ramón y Cajal introduced the 
notion that dementia may be a result of synaptic degeneration (Cajal SR, 1928). In all AD 
cases, impairment and loss of synapses is an invariant feature that occurs at early stages. 
Quantification through electron microscope and immunohistochemical staining using 
synaptic markers have revealed a significant reduction of synapse density and synaptic 
proteins in the AD brain, of which hippocampus and cerebral cortex were the two most
affected regions (Davies et al., 1987; Bertoni-Freddari et al., 1989; Masliah et al., 2001). 
Consistently, it had been shown by biochemical and immunohistochemical analysis that 
both pre-synaptic and post-synaptic components were greatly reduced in AD brains 
(Reddy et al., 2005). The synaptic loss occurs before neuronal cell loss, suggesting 
synaptic degeneration is an early event in disease pathogenesis (Davies et al., 1987; 
DeKosky et al., 1990). Moreover, the degree of impairment in synapse structure and loss 
of synaptic function are best correlated with the severity of disease in memory decline 
(Sze et al., 1997; DeKosky et al., 1990; Terry et al., 1991; Shanker and Walsh, 2009). 
????????????????????????????????????????????????????????????????????????genesis, 
???????????????????????????????????????????????????????????????????????????????????????
oligomers and the severity of synaptic density loss and cognitive impairment (Haass et 
al., 2007; Laferla et al., 2007; Shankar and Walsh, 2009). Treatment with ????????????
oligomers greatly reduced spine density (Wei et al., 2010). Dendritic spine formation was 
????????????????????????????????????????????????????????????????????-???????????????
????????????????? ???????????????????????????????????????????????????e (Spires-Jones et 
??????????????????????????????????????????????????????????????????????????????????
synaptic transmission and plasticity. The excitatory synaptic transmission is strictly 
regulated by two active ionotropic glutamate receptors, NMDA receptors (NMDAR) and 
????????????????????????????????????????????????????????????????????????????
remove receptor sites responsible for excitatory synaptic transmission, block 
NMDAR/AMPAR and the reuptake of neurotransmitter glutamate, and shift the 
activation of the NMDAR-dependent signaling pathway involving long-term potentiation 
(LTP) induction to the signaling pathway involving long-term depression (LTD) and 
synaptic loss, although the underlying mechanism remains unclear (Shanker et al., 2007; 
Li et al., 200?????????????????????????????????????????????????????????????????????????????
evidenced by electroencephalogram (EEG) recordings from cortical and hippocampal 
networks (Palop and Mucke, 2010). The other AD hallmark is the presence of 
neurofibrillary tangles containing hyperphosphorylated tau protein. In the studies without 
tangles, mice with overexpression of human tau displayed synaptic degeneration, 
showing that the soluble and oligomeric tau is the synaptotoxic species. In both mouse 
models and human AD brains with tauopathy, neurons with neurofibrillary tangles were 
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found not only to have fewer synapses onto their soma, but also to have significantly 
fewer synaptic proteins than those neurons lacking tangles (Katsuse et al., 2006). 
Since synaptic loss and dysfunction represents one of the key features of AD, 
efforts to protect synapses may be a feasible strategy in treating AD. Studies using 
insulin-sensitizing compounds (chiro-inositols) demonstrated potential to treat AD by 
protecting synapses against ????????????????????????????? ??????????????????????????????
al., 2009; Pitt et al., 2013). The dietary ingredient docosahexaenoic acid (DHA) is known 
to be able to preserve synaptic function and memory in aged individuals. It is also able to 
function upon ?????????????????????????????????????????????????????????????????????
Oster and Pillot demonstrated that DHA improved neuronal and brain function in an AD 
mouse model (Oster and Pillot, 2010). These studies raised the possibility of finding 
therapeutic strategy focusing on protection of synaptic function in treating 
neurodegeneration, particularly in AD.  
????????????????????? ?????????????????????????????????????????????????????? ????
????????????????????????????????????????????????????????????????????????iscovered to be 
the main toxic species which adversely affect the synaptic structure and plasticity (e.g. 
LTP) underlying the pathological mechanism for AD. Additional evidence from clinical 
trials showed that removing plaques did not reverse neuronal damage, which indicated 
soluble oligomers, rather than insoluble fibrils, as the primary toxic species. This was 
also supported by numerous other studies (Klyubin et al., 2005; Kayed et al., 2005; 
Shankar et al., 2007; Selkoe, 2008). Therefore, future study on treating AD by focusing 
??????????????????????????????????????????????????????????????????.
1.1.6 Mouse Models of Alzheimer’s Disease
In an attempt to better understand the pathological progression of AD, scientists 
have developed a number of transgenic mouse models based on the known genetic 
mutations known to be associated with pathological changes, especially in early-onset 
FAD. The first-ever transgenic mouse model with AD pathology was created two 
decades ago and many more models were created after that, greatly facilitating basic 
research on AD development and drug screening (Cavanaugh et al., 2014). Three 
different categories of transgenic mouse lines were established based on the two 
???????????????????????????????????????? ??????????????????????hology (amyloidopathy), 
transgenic mouse lines with tau pathology (tauopathy) and transgenic mouse lines with 
both amyloidopathy and tauopathy.
Distinct mutations within the APP gene: Swedish (K670N/M671L), London 
(V717I), Indiana (V717F) and Florida (I716V), have been associated with development 
of amyloid pathogenesis in FAD, and were subsequently named after the places in which 
they were discovered (Chartier-Harlin et al., 1991; Goate et al., 1991; Eckman et al., 
1997). Since then, researchers have developed a number of transgenic mice that express 
human APP proteins with one or more of these mutations. In general, these transgenic 
???????????????????????????????????????????????????????????????????????????????????????????
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the mouse lifetime, some followed by neuroinflammation. Furthermore, these transgenic 
mice present cognitive/memory deficits and behavioral abnormalities. The first 
generation of transgenic mouse models is monogenic with one or multiple mutations. The 
first transgenic AD mouse model, named PDAPP, was created by Games et al. in 1995 
and had mice expressing APP with Indiana mutation (V717F) driven by platelet-derived 
?????????????????????-??????????????????? ???????????????-14 fold greater expression 
???????????????????????????? ???????????? exhibited synapse and memory loss 
(Games et al., 1995). Dr. Karen Hsiao Ashe developed Tg2576 mouse one year after this 
APP-expressing model (isoform 695) with the Swedish mutation (K670N/M671L) under 
the direction of hamster prion protein (PrP) promoter (Hsiao et al., 1996). To date, this is 
one of the most well-characterized and widely-used AD mouse models. Tg2576 mice 
display normal cognition early in life, and then develop cognitive deficits during aging 
(12-24 months). These mice start to show signs of progressive impairment on spatial and 
learning memory, and also demonstrate deficits in working memory at 12 months, which 
is considered a presymptomatic AD stage. Memory deficits become worse from 12 to 18 
months, which is considered an intermediate symptomatic stage. Tg2576 mice develop 
??????????????????? ???????????????????????????????????????????????????????????????????
hippocampal CA1 region, but no neuronal loss or neurofibrillary tangles containing tau. 
Synaptic plasticity is also impaired as evidenced by reduced LTP in both the CA1 and 
dentate gyrus (DG) sub-regions of hippocampus. Eventually, more and more transgenic 
AD mouse models of first generation were created to overexpress APP with all three 
(Swedish, London and Indiana) mutations including C3-3 (APPSwe), APP23, J9, 
TgCRND8 and J20 (Borchelt et al., 1996; Sturchler-Pierrat et al., 1997;  Hsia et al., 1999; 
Mucke et al., 2000; Chishti et al., 2001). Some of the models, such as J20, have more 
???????????????????????????????????????????? ??????deficits appear as early as 4 months 
of age. Moreover, impairment in synaptic plasticity can also be observed in J20 mice 
between 3 to 6 months of age.  Mutations in PSEN are associated with early onset AD in 
humans. While amyloidopathy in transgenic mice is addressed by creating APP mutations 
????????????????????????????????????????????????????????????????????????????????????????
mouse models. To address the pathological role of hyperphosphorylated tau protein and 
neurofibrillary tangles in AD pathogenesis, researchers have developed AD mouse 
models that overexpresses human tau protein (MAPT) with certain mutations, such as 
Tau V337M, PS19 (Tau P301S), Tau P301L, Tg30 (Tau G272V, P301S) (Tanemura et 
al., 2002; Allen et al., 2002; Terwel et al., 2005; Schindowski et al., 2006). Among them, 
the PS19 mice is one of the most widely used tauopathy models, carrying tau protein with 
P301S mutation and developing neuronal loss and cerebral atrophy from 8 to 12 months 
of age, primarily in the hippocampus and then later spreading to other brain regions. Tau 
aggregates can be detected as early as 1.5 months of age prior to neurofibrillary tangles 
formation without any amyloid plaques. PS19 mice also display age-associated cognitive 
deficits in spatial learning and memory at 7 to 10 months of age. Notably, mutations in 
the tau protein are increasingly linked to FTD. In an attempt to establish a more AD-
relevant tauopathy model, researchers crossed tau knockout mice with human tau protein 
overexpressing mice, generating a mouse line (Htau) expressing only human tau protein. 
However, a minimal neurofibrillary tangle was developed in this model (Andorfer et al., 
2003).
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By expressing APP mutations and PSEN mutations (M233T, L235P, M146L, 
L286V), researchers established the second generation of mouse models such as 
APPSLPS1M146L, APPSLPS1ki, 5×FAD (Tg6799) etc. (Langui et al., 2004; Casas et 
al., 2004; Oakley et al., 2006). Notably, biogenic or polygenic protein mutations caused 
early and aggressive amyloid pathology. For instance, 5×FAD mouse displayed many 
AD-???????????????????????????????????????????????????????????????????????????????????
beginning at around 2 months of age. Plaques are abundantly observable throughout the 
brain (cortex and hippocampus) by 6 months of age. Synaptic and neuronal loss were also 
observed at 4 months of age accompanying declining spatial learning ability. 
Additionally, to study hereditary cerebral amyloid angiopathy (CAA), researchers created 
mouse lines, such as APPDutch and ARC48, by overexpressing APP with E693Q 
(Dutch) or E693G mutations (Herzig et al., 2004; Cheng et al., 2004). In order to 
replicate both neuropathological features of AD, researchers developed the fourth 
generation of mouse models, represented by a triple transgenic mouse (3×Tg-AD) 
expressing human APP protein with Swedish mutations, PSEN with M146V mutation 
and human tau protein with P301L mutation (Oddo et al., 2003). This mouse model 
?????????????????????????????????????????????????????????????????????????????????????
early time (6 months of age), and tau hyperphosphorylation and aggregates seen at a later 
time (12-15 months of age). Behavioral changes occur early with cognitive impairment 
occurring at 4 months of age, and learning and memory deficits at 6.5 months of age. 
Thi?????????????????????????????????????????????????????????????????????????????????????
deficits appear prior to the formation of amyloid plaque or neurofibrillary tangles 
(Morrissette et al., 2009; Schaeffer et al., 2011).
Another approach to enable inducible expression of transgenic protein was 
established by researchers to create the third generation of AD mouse models, with a 
representative model named rTg4510 (Santacruz et al., 2005). The rTg4510 mouse model 
is a tauopathy model that expresses a repressible form of human tau transgene containing 
the P301L mutation. This transgene is located downstream of a tetracycline (Tet) 
response element (TRE), and its expression is driven by a second transgene containing 
tetracycline-controlled transactivators (tTA) under control of a promoter such as 
CaMKII-????????????????????????????????????????????????????????????????????????
????????????????????????????-tTA mice, and the expression can be turned off by 
administration of doxycycline (Dox), a tetracycline analogue. This is called Tet-off 
system. This inducible genetic model enables researchers to investigate half-life and 
reversibility of phenotypes in FAD. This model displays cognitive impairment by 3 
month of age, neurofibrillary tangles by 4 months of age, and synaptic loss by 6 months 
of age (Santacruz et al., 2005; Spires-Jones et al., 2006).
The fourth generation of AD mouse models features a knock-in approach, with a 
representative model named APPNL-G-F (Saito et al., 2014). This recently developed 
approach has the advantage of providing more specific expression patterns and levels, in 
contrast to potential artifacts produced by general APP overexpression. Moreover it also 
avoids the potential complication of disrupting unknown genomic loci (Onos et al., 
2016). APPNL-G-F mice express APP at wild-type levels with cell-type and temporal 
specific?????????????????????????????????????????????????????????????????????????????????
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three APP mutations with respective functions: KM670N/M671L (Swedish mutation; 
???????????????????????????????????????????????? ???????????????????????????????????????
and E693?????????? ??????????????????????????????????????? ??????????????????????
plaques and gliosis (astrocytosis and microgliosis) at 3 months of age, synaptic loss at 4 
months of age, and age-related cognitive impairment (Y-Maze) at 6 month of age (Saito 
et al., 2014). 
AD mouse models for LOAD are more challenging due to the aforementioned 
environmental factors, and the complex genetic factors, many of which remain unknown. 
Since APOE is most often associated with LOAD, researchers generated the  GFAP-
APOE4/APOE KO mouse model which expresses human apolipoprotein E4 (hAPOE4) 
(Sun et al., 1998). The hAPOE4 is expressed under the direction of the GFAP promoter 
in the absence of endogenous mouse APOE (mAPOE) by crossing to APOE KO mice. 
These mice display deficits ??????????????????????????????????????????????????
homozygous GFAP-APOE4/APOE KO mouse develop complete AD phenotype 
suggesting the requirement of additional genetic and/or environmental factors (Onos et 
al., 2016).
AD mouse models are extremely useful tools during various phases of the drug 
discovery. Rational drug discovery processes begins with target identification and target 
validation, followed by high-throughput library screening and lead compound 
optimization. After that, lead compounds are tested in preclinical studies and eventually 
clinical trials. Among them, AD mouse models are heavily used in the target 
identification and validation process, as well as in preclinical studies (Hall and Roberson, 
2012). Examples of commonly used mouse models of AD are shown in Table 1-2.
1.2 Neurodegenerative Diseases
1.2.1 Heat Shock Response and Heat Shock Proteins 
The heat shock response is a high evolutionarily-conserved response in living 
cells that protects against intracellular and extracellular stress in all organisms (bacteria, 
plants, animals). It was firstly discovered in the early 1960s in a Drosophila model by 
Ritossa and was originally described as the biochemical response of cells to 
environmental heat (Ritossa, 1962). Later on, researchers discovered this activated heat 
shock response was also elicited by various other stressors, including environmentally 
stressed conditions (oxidative stress, low temperature, altered pH, exposure to alcohol, 
toxins, heavy metals and detergents) and pathological stressed conditions (microbial 
infections, tissue trauma, genetic lesions) (Schlesinger, 1990; Welch et al., 1991). The 
heat shock response acts as an essential self-defense mechanism for protecting cells from 
both intracellular and extracellular harm. A common consequence of cells undergoing 
various stresses is the misfolding or denaturing of proteins that usually leads to protein 
accumulation and aggregation. General inhibition of heat shock response results in these
aforementioned anomalies.
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Table 1-2 Generations of Commonly Used Mouse Models of AD.
Generation Allele(s) Protein
Model
name
Transgene(s) Mutation(s) Promoter(s) Reference(s)
1st
Generation 
Transgenic 
(monogenic)
?? PDAPP hAPP V717F PDGF-? Games et al., 1995
Tg2576 hAPP K670N, M671L Hamster prion protein Hsiao et al., 1996
C3-3
(APPSwe)
hAPP K670N, M671L mouse prion protein 
promoter
Borchelt et al., 1996; 
Savonenko et al., 2003
APP23 hAPP K670N, M671L murine Thy1 promoter Sturchler-Pierrat et al., 
1997
J9 hAPP K670N, M671L, 
V717F
PDGF-? Hsia et al., 1999
J20 hAPP K670N, M671L, 
V717F
PDGF-? Mucke et al., 2000
TgCRND8 mAPP K670N, M671L, 
V717F
Hamster prion promoter Chishti et al., 2001
APPDutch hAPP E693Q murine Thy1 promoter Herzig et al., 2004
ARC48 hAPP K670N, M671L, 
V717F ; E693G
PDGF-? Cheng et al., 2004
Tau JNPL3 MAPT (htau) P301L mouse prion protein 
promoter
Lewis et al., 2000
Tg214 MAPT (htau) V337M PDGF-? Tanemura et al., 2002
PS19 MAPT (htau) P301S murine Thy1 promoter Allen et al., 2002
Htau MAPT (htau) mTauKO Tau, Thy1 Andorfer et al., 2003
Tau P301L MAPT (htau) P301L murine Thy1 promoter Terwel et al., 2005
Tg30 MAPT (htau)  G272V, P301S murine Thy1 promoter Schindowski et al., 
2006
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Table 1-2 (Continued).
Notes: Modified with permission. Cavanaugh SE, Pippin JJ, Barnard ND. (2014). Animal models of Alzheimer disease: historical 
pitfalls and a path forward. ALTEX. 31, 279-302. Onos KD, Sukoff Rizzo SJ, Howell GR, Sasner M. (2016). Toward more predictive 
genetic mouse models of Alzheimer's disease. Brain Res Bull. 122, 1-11.
Generation Allele(s) Protein
Model
name
Transgene(s) Mutation(s) Promoter(s) Reference(s)
2nd
generation 
Transgenic 
(Bigenic/
polygenic)
?? PS/APP hAPP, hPSEN1 APP K670N, M671L; 
PSEN M146L
Hamster prion protein 
(APP), HMGCoA 
reductace (PSEN)
Holcomb et al., 1998
APPSLPS1
M146L
hAPP, hPSEN1 APP K670N,M671L, 
V717I; PSEN M146L
Thy-1 (APP), HMGCoA 
reductace (PSEN)
Langui et al., 2004
APPSLPS1ki hAPP, hPSEN1 APP K670N, M671L, 
V717I; PSEN M233T, 
L235P
Thy1 (APP) Casas et al., 2004
5×FAD
(Tg6799)
hAPP, hPSEN1 APP K670N, M671L, 
I716V, V717I; PSEN1 
M146L, L286V
Thy1 Oakley et al., 2006
A?/tau 3×Tg-AD hAPP, hPSEN1, 
MAPT (htau)
APP K670N, M671L; 
PSEN1 M146V; tau 
P301L
Thy1 promoter (APP, 
Tau)
Oddo et al., 2003
3rd
generation
Inducible 
transgenic
Tau rTg4510× 
CamkII?-
tTA
MAPT
(htau)
P301L ??????? Santacruz et al., 2005
4th
generation
Knock-in ?? APPNL-G-F hAPP APP KM670N, M671L, 
APP I716F, APP 
E693G (Arctic)
APP Saito et al., 2014
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Traditional heat shock response is mediated by activation of heat shock 
transcriptional factors (HSFs). In invertebrates, such as yeast and Drosophila, there is a 
single heat shock factor (HSF1) mediating transcriptional activation of heat shock 
response. However, vertebrates have a known family of five HSF members: HSF1, 
HSF2, HSF3, HSF4 and HSF5. HSF1 can be activated by several stressors and upregulate 
several heat shock proteins such as Hsp70, Hsp40, Hsp27 etc. In contrast, HSF2 is only 
activated during early development and differentiation. HSF3 is only expressed in birds. 
HSF4 functions as a repressor of heat shock proteins. HSF5 is a newly discovered protein 
and its function remains largely unknown (Fan, 2012). Among these five factors, HSF1 
plays the most important role against various stresses. It is essentially a master 
transcriptional factor in mammalian cells, acting on conserved DNA binding sites called 
heat shock elements (HSEs). In non-stressed conditions, HSF1 is localized to the 
cytoplasm in the form of an inactive monomer bound to Hsp90. Under certain stresses, 
stress-induced activation of heat shock response is completed by disassociation of HSF1 
with Hsp90, HSF1 trimerization, phosphorylation, and translocation to the nucleus, where 
the DNA binding ability of HSF1 is much improved. The nuclear HSF1 interacts with 
HSEs in the promoter region of target genes that induce protein expression of several heat 
shock proteins (Sarge et al., 1993) (Figure 1-2).
Heat shock proteins (HSPs) are a group of a multi-gene family of proteins that are 
highly conserved and ubiquitously expressed in cells. They are also involved in protein 
transportation, turn-over and regulation. The principle heat shock proteins with chaperon 
activity are classified into six main sub-families based on their molecular weight: 
Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and the small molecular weight heat shock 
proteins (less than 40 kDa) (Muchowski and Wacker, 2005). Heat shock proteins function 
as molecular chaperones to facilitate protein synthesis and assembly, and folding of 
nascent polypeptides, or correcting misfolded proteins to prevent protein aggregation. 
Heat shock proteins are also involved in other cellular events, such as protein 
transportation and degradation, signal transduction, stimulation of innate and adaptive 
immune systems, cell growth and differentiation, and protection from apoptosis (Nollen 
and Morimoto, 2002; Lanneau et al., 2008). Different isoforms of heat shock proteins 
from the same family can localize in different subcellular locations and their expression 
can be either constitutive or stress-inducible (Lanneau et al., 2008). 
1.2.2 Hsp90 and Hsp70: Structure-based Distinct Functions
Of all heat shock proteins, Hsp90 and Hsp70 are the two most abundant proteins. 
Of these two proteins, Hsp90 is more prevalent than Hsp70. Hsp90 has two isoforms, the 
?????????????????????????????????????????????????????????????????????????????????
form), which are both constitutively expressed and comprise of 1~2% of cellular proteins 
under non-stressed conditions. Hsp90 exists ??????????????????????????????????????????
??????????????????????? ???????????????????????????????????????????????????????????????
isoforms (Sreedhar et al., 2004). Each homodimer is made up of monomers that consist 
of three main domains: N-terminus domain, middle domain and C-terminus domain. 
There is also a flexible linker between N-terminus domain and middle domain (M-
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Figure 1-2 HSF1-mediated Heat Shock Response.
Modified with permission. Westerheide SD, Morimoto RI. (2005). Heat shock response 
modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 280, 
33097-33100.
Heat shock response can be stimulated under both physiological states and pathological 
states.  Stress and small molecules can also cause heat shock response, which is mainly 
mediated by the master transcriptional regulator HSF1, leading to expression of heat 
shock proteins. Known functions of heat shock proteins include, but not limit to, 
regulation of signaling pathway, aiding in protein synthesis, folding, transportation and 
degradation, activation of immune system, prevention of apoptosis.
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domain). The N-terminus domain contains an ATPase and sites for co-chaperone binding 
with biochemical functions responsible for the ATPase activity of Hsp90. Importantly it 
is also the binding site for small molecules including nucleotides, Geldanamycin (GA), 
17-AAG, radicicol. The C-terminus domain serves as the docking site for dimerization 
and co-chaperone binding, such as cdc37, p23 etc. The M-domain is thought to be the 
major site for client protein binding (Figure 1-3) (Whitesell and Lindquist, 2005). So far, 
there are more than 200 Hsp90 client proteins identified (Picard, 2008). These client 
proteins include a large variety of signal transduction molecules, kinases, and receptors 
involved in controlling cell survival and proliferation. Some notable client proteins are 
chaperones and relatives (p23, Hsp70, Hsp60, etc.), transcription factors (HSF1, p53, 
p73, BCL-6, etc.), kinases (AKT/PKB, TrkB, AMPK, Cdk, CamK, MAPK, GSK, 
??????????????????????????-??????????????????????????????????????????????????????????-
synuclein etc.) (Picard, 2008). Many of these proteins are closely related to cancer cell 
survival and proliferation (Kamal et al., 2004). HSF1 is a client protein of Hsp90 (Zou et 
al., 1998). Upon inhibition of Hsp90, HSF1 is released for transcriptional activation 
(Taipale et al, 2010) and induces protein expression of inducible Hsp70. Given the well-
known function of Hsp90 on stabilizing client proteins, Hsp90 inhibition was also found 
to promote protein degradation through the ubiquitin-proteasome (UPS) pathway (Li and 
Buchner, 2013).
The structure of Hsp70 contains an N-terminus domain, which is an ATPase 
domain/Nucleotide binding domain (NBD), and a C-terminus domain that is also the 
substrate binding domain (SBD) (Evans et al., 2011). There are two isoforms of Hsp70, 
heat shock cognate protein 70 (HSC70) and inducible form of Hsp70 (iHsp70). HSC70 is 
constitutively expressed, while inducible Hsp70 (iHsp70) is poorly expressed in resting 
conditions or induced to express in stressed conditions. As a major molecular chaperone, 
The CBD of Hsp70 is a key component in folding catalysts that aids in a wide 
variety of protein processes including folding of freshly synthesized protein, protein 
assembly, refolding of misfolded proteins and protein aggregates, protein translocation in 
membrane and control of regulatory proteins’ activity. Thus, Hsp70 has a housekeeping 
function in mammalian cells that governs general protein quality control. This activity 
appears to rely on the transient binding interaction of the substrate binding domain (SBD) 
with hydrophobic short peptide segments of the substrate proteins controlled by N-
terminus ATPase domain (Mayer and Bukau, 2005). The roles of Hsp70 in folding newly 
synthesized proteins can be separated into the following 3 activities: 1) prevention of 
protein aggregation which is completed with its co-chaperone of the J-domain protein; 2) 
facilitating folded proteins to the native state (mechanism remains unclear); 3) refolding 
or solubilization of aggregated proteins, which is performed through mutual cooperation 
with chaperone proteins of the Hsp100 family (Hsp104/ClpB) (Mayer and Bukau, 2005). 
While these two major chaperone proteins, Hsp70 and Hsp90, are both richly 
localized in synaptic compartments (Moon et al., 2001; Stetler et al., 2010), little is 
known regarding their synaptic functions. Given that there is a common misconception of 
targeting Hsp90 inhibition on treating human diseases, such as cancers and 
neurodegenerative diseases, Hsp70 inhibition is indeed thought to be able to constrain 
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Figure 1-3 Structure and Functions of Hsp90 Dimer.
Modified with permission. Whitesell L, Lindquist SL. (2005). Hsp90 and the chaperoning 
of cancer. Nat Rev Cancer 5, 761-772.
The protein structure, location of binding sites and their biochemical functions are 
indicated for HSP90.
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heat shock response. In contrast, Hsp90 inhibition not only promotes degradation of 
client proteins, but also causes HSF1-mediated heat shock-like response activation along 
with other important synaptic regulation machinery, as discovered by the current study.
1.2.3 Heat Shock Proteins in Neurodegeneration
To maintain cellular integrity of the proteome, the normal protein quality control 
process determines whether an existing protein should be folded or degraded, and ensures 
that the newly synthesized protein undergoes the correct folding rather than misfolding 
and/or aggregation. Neurodegenerative diseases (AD, PD, HD, FTDP, etc.) are 
commonly characterized by abnormalities in the process of protein quality control, 
leading to aberrant formation of distinct pathological misfolded proteins and/or protein 
aggregates. In addition to those listed in Table 1-1, other disease-causing deposited 
proteins include hyperphosphorylated tau in FTD with Parkinsonism; Atrophin-1, ataxins 
or androgen receptor (AR) in other polyglutamine diseases (Ross et al., 2004). Since most 
pathological events start with formulation of these protein aggregates, targeting clearance 
of these misfolded proteins and/or protein aggregates is a logical therapeutic idea for 
treating neurodegenerative diseases.
While the clearance of misfolded proteins and/or protein aggregates following 
Hsp90 inhibition is ill-defined, it is generally accepted that it requires induction of a heat 
shock-like response involving HSF1-mediated upregulation of other chaperone proteins 
such as iHsp70 and its co-chaperones (e.g., Hsp40/DNAJ, Hsp27, etc.). Studies have 
shown the co-localization of various chaperone proteins (such as Hsp70) with protein 
aggregates that are characteristic of AD, PD, FTDP and the polyglutamine disease 
(Muchowski et al., 2005). Protein overexpression of select heat shock proteins (Hsp70, 
Hsp40 and Hsp27) has exhibited a certain level of neuroprotection in several animal 
models of neurodegenerative diseases. For instance, Hsp70 overexpression has been 
????????????????????????????????????????????????in vitro AD model (Magrané et al., 
???????????????????????????????????????????????????????????-synuclein mediated 
toxicity in a drosophila model of PD (Auluck et al., 2002). The aforementioned 
neuroprotective observations were due to elevation of a single heat shock protein. 
Induction of a set of various heat sock proteins can be more potent in neuroprotection 
than overexpression of one type of heat shock protein. Heat shock proteins may show 
neuroprotection via preventing interactions of misfolded protein and promotion of protein 
degradation (Brown, 2007). In mammalian cells, the master transcription regulator HSF1 
controls induction of stress-induced heat shock proteins. It thus would be promising to
discover a strategy to regulate heat shock proteins via HSF1 for neurodegenerative 
diseases that produce misfolded proteins and/or protein aggregates (Neef et al., 2011).
1.2.4 Hsp90 Inhibitors
Since many Hsp90 client proteins control various important cellular events such 
as cell survival, proliferation and apoptosis, Hsp90 function is closely associated with 
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health. In fact, Hsp90 has been found to play an important role in disease progression. 
For instance, Hsp90 was found to be constitutively overexpressed at intracellular levels 2 
to 10-fold greater in tumor cells compared to normal cells (Ferrarini et al., 1992) and the 
inducing molecule including NF-?????????????????????????????????????????????????????
be an important target in cancer therapy. Various natural and synthetic Hsp90 inhibitors 
have been developed for preclinical anti-tumor activity. Common Hsp90 inhibitors target 
the ATP binding site at the N-terminus inactivating ATPase, ultimately resulting in 
release of Hsp90 client proteins such as HSF1.
There are two major classes of Hsp90 inhibitors: ansamycin backbone based 
inhibitors such as geldanamycin (GA) and its derivatives, and radicicol based inhibitors 
including radicicol and its derivatives. GA was firstly discovered by DeBoer et al. in the 
early 1970s in the broth and the mycelium of Streptomyces (DeBoer et al., 1970). The 
chemical structure of GA was established and reported by Sasaki et al. later that year 
(Sasaki et al., 1970). The antitumor effects of GA were reported 7 years later by two 
different groups through in vitro studies (Li et al., 1977; Price et al., 1977). For a long 
time, little to no progress was made, that is until a breakthrough discovery made by 
Ferrarini et al. in 1992, which elucidated the role of heat shock proteins in cancer 
progression (Ferrarini et al., 1992). GA was found to be able to restructure cancer-related 
proteins (Blagosklonny et al., 1995). GA was then introduced to be used in animal studies. 
However, GA exhibited high toxicity in the liver, kidney and other organs, too extreme 
for in vivo use (Supko et al., 1995), so researchers focused on generation of GA 
derivatives with less toxicity. 17-AAG (17-N-allylamino-17-demethoxygeldanamycin, 
also known as tanespimycin) was synthesized and found to possess lower in vivo toxicity 
and better stability than GA. Although Hsp90 binding affinity for 17-AAG was weaker 
than for GA, 17-AAG exhibited biologic antitumor activity at almost the same 
concentrations with GA in malignant cell lines (Schulte and Neckers, 1998). In 1999, 17-
AAG entered the clinic trials for cancers. Due to the poor chemical solubility of 17-AAG, 
another GA derivate named 17-DMAG (17-Dimethylaminoethylamino-17-
demethoxygeldanamycin, also known as alvespimycin) was developed with better 
solubility and entered first human study in 2004.
The radicicol backbone based Hsp90 inhibitors do not cause hepatotoxicity. 
Although, radicicol is not suitable for therapeutic applications due to in vivo instability 
(Soga et al., 1999), researchers have thus focused on the development of radicicol 
derivatives with improved stability. NexGenix Pharmaceuticals (now acquired by 
Oncosynerge. Inc.) engineered and synthesized a pochoxime series of compound with the 
leading compound NXD30001 (new name OS47701) and OS47720 (also known as 
pochoxime C) (Barluenga et al., 2009; Wang et al., 2009; Zhu et al., 2010). NXD30001 
displayed in vivo stability and an improved safety profile. It is also CNS-permeable and 
binds with Hsp90 with high affinity. NXD30001 induced expression of heat shock 
proteins (iHsp70, Hsp60, Hsp40 and Hsp27) in a dose, time and HSF1-dependent manner 
with a comparable efficacy to17-AAG in breast cancer cells (Cha et al., 2014). 
Hsp90 inhibitors were first introduced in treating neurodegenerative diseases by 
Waza et al. in 2005, who reported 17-AAG’s ability to ameliorate motor impairments in 
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the spinal and bulbar muscular atrophy (SBMA) transgenic mouse model, through 
induction of heat shock protein expression and reduction of monomeric and aggregated 
mutant androgen receptor (AR) (Waza et al., 2005). Two other groups (Luo et al., 2007; 
Dickey et al., 2007) have also targeted Hsp90 inhibition in tau pathology by using 
synthesized Hsp90 inhibitors, and both groups were able to observe reduction of 
aggregated tau. However, no follow-up study demonstrating in vivo efficacy with 
improved symptoms has been reported, assuming poor or very limited efficacy produced 
from these in vivo applications. More recent studies of NXD30001 have shown induction 
of heat shock proteins and protective profiles against mutated SOD1 in motor neuron 
culture models of fALS (Cha et al., 2014). We therefore proceeded to evaluate the 
therapeutic effects of the Hsp90 inhibitor, OS47720, in both an in vitro cell culture 
models and an in vivo Alzheimer’s disease mouse model.
1.3 Hypothesis and Rationale
1.3.1 Hypothesis
We hypothesize that OS47720 may be a feasible Hsp90 inhibitor suitable for 
further drug development as an AD therapeutic agent whose actions are HSF1-dependent.
1.3.2 Rationale
Alzheimer’s disease (AD) is a progressive neurological disorder afflicting 
???????????????????????????????????????????????????????????????????????????????????????
???????????????????????- ?????-secretases, but have yielded minimal clinical success 
(Becker et al., 2008; Honig, 2012). A family of chaperone proteins has been shown to be 
involved in the protein assembling and disassembling processes. Nowadays, the 
importance of chaperones in the quality control of proteins has been widely understood. 
Hsp90, as one of the most abundant of the chaperone protein family, functions in 
assisting proper protein folding, stabilizing proteins against cellular stress, and aiding 
protein degradation (Young et al., 2001).  Because many aberrant proteins involved in 
tumor growth and survival (e.g., protein kinase B/AKT) are also stabilized by Hsp90, 
Hsp90 inhibitors have long been recognized as candidate drugs for cancer treatment 
(Whitesell and Lindquist, 2005; Neckers, 2007).  Hsp90 is also implicated in 
neurodegenerative diseases (Luo et al., 2010), such as AD) and PD. Several reports also 
showed that Hsp90 inhibitors reduced abnormal protein aggregations of tau (Dickey et al., 
???????????-synuclein (Putcha et al., 2010), possibly via the activated heat shock proteins 
(e.g., iHsp70 etc).
Since both Hsp90 and Hsp70, the two most abundant forms of chaperone proteins, 
are localized at synapses and around amyloid plaques, Dr. Liao’s group has sought out to 
study the effects of Hsp90 inhibitors in synaptic functions, beginning as early as 2008. Dr. 
Chen, a former graduate student in her lab, made the initial discovery of a novel aspect of 
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the Hsp90 inhibitor, using a commercial compound 17-AAG in protecting primary 
???????????????????????-induced synaptic toxicity. I participated in that project and was 
able to later reproduce Dr. Chen’s in vitro observations, in which 17-AAG was found to 
induce heat shock protein, upregulated presynaptic and postsynaptic proteins in cultured 
??????????????????????????????????????????????????????????????????????? able to further 
discover 17-AAG’s neuroprotective effect in preventing loss of contextual conditioned 
????????? ???????????????????????????-impaired in contextual fear conditioning assay. 
Together, we published a brief report in “The Journal of Neuroscience”. Since 17-AAG 
has limited CNS-permeability (Zhu et al., 2010), I then tested the CNS-permeable 
compound OS47720, obtained from a private Oncology company, in both in vitro and in 
vivo studies. In the in vitro study, OS47720 induced a heat shock-like response 
comparable to that induced by 17-AAG (e.g., upregulated not only multiple HSPs but 
also pre- and post-synaptic proteins), and furthermore protected loss of synaptic proteins 
???????????????????????????????????????????? ??????????????????????????????o
observable hepatotoxicity, as was not the case with GA or 17-AAG. The efficacy of 
OS47720 in an AD mouse model (Tg2576) was further examined. Given that OS47720 
targets Hsp90 inhibition by releasing HSF1, HSF1-mediated transcriptional and synaptic 
regulation was further examined.
1.3.3 Specific Aims
Aim 1. To test whether the Hsp90 inhibitor 17-AAG shows a neuroprotective 
?????????????????????????????????in vitro and in vivo.
Aim 2. To test OS47720’s pharmacological and in vivo efficacy in early and 
middle symptomatic Tg2576 mice.
Aim 3. To investigate the molecular mechanism of HSF1 mediated regulation 
underlying OS47720’s therapeutic effects.
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CHAPTER 2.   MATERIALS AND METHODS
2.1 Animal Studies
2.1.1 Mouse
All animal procedures were performed in accordance with the Animal Scientific 
Procedures Act and with the approval of the Institutional Animal Care and Use 
Committee (IACUC) at the University of Tennessee Health Science Center (UTHSC). 
The breeding pair of Tg2576 mice was originally purchased from Taconic (Stock#: 1394) 
and maintained on a C57BL6/J background. The breeding pair of HSF1 mice was ordered 
from the Jackson laboratory (Stock#: 018582) and maintained on the C57BL6/J 
background. The Hsp70-mPlum reporter mouse line was generated from Dr. Anna M. 
Planas (Institute for Biomedical Research of Barcelona, Spain) and provided to us via 
collaboration.
2.1.2 Genotyping
Tail tissue (about 2mm) from young (< 21 d) mice (without anesthesia) or adult (> 
21 d) mice (with topical anesthesia) was taken by using a sterilized scissors. Tissue was 
immediately used for DNA extraction or kept frozen at -20°C for future use. DNA was 
isolated following a phenol-chloroform extraction protocol (The Jackson laboratory, Inc.). 
PCR was performed with KAPA Mouse Genotyping Kits (Kapa Biosystems, Inc.). 
Tg2576 mice were genotyped by PCR with the following primer sequences (5' -> 3'): 
Tg2576 transgene (transgenic) forward AGG ACT GAC CAC TCG ACC AG; Tg2576 
transgene reverse CGG GGG TCT AGT TCT GCA T; Tg2576 internal positive control 
(wild type) forward CTA GGC CAC AGA ATT GAA AGA TCT; Tg2576 internal 
positive control reverse GTA GGT GGA AAT TCT AGC ATC ATC C. HSF1 mice 
colony were genotyped by PCR with the following primer sequences: HSF1 mutant 
forward CGG TCG CTA CCA TTA CCA GT; HSF1 mutant reverse CCA AGG AGA 
TGT AGT GAG GTC TG; HSF1 wild type forward CTC CAT CTC CAG CCT ACA GC; 
HSF1 wild type reverse AGA GTG CTG CTG GAC AGA GG.
2.1.3 Intracerebroventricular (i.c.v.) Cannulation
Surgery was performed under aseptic conditions in a stereotactic instrument 
(Stoelting Co., Wood Dale, IL, USA). Mice were anesthetized by intraperitoneal injection 
of xylazine/ketamine (13/87 mg/kg). Ketamine supplements (10 mg/0.1 ml) were given 
intraperitoneally (i.p.) as needed throughout surgery. A small incision was made, and the 
skull was then exposed and cleaned and a small burr hole was drilled using a dental drill 
or Dremal rotary tool. One unilateral guide cannula (Plastics One; C315GS-5-SPC, cut 
1.5 mm below the pedestal) was implanted above the dorsal lateral ventricle using a 
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stereotaxic instrument (KOPF Instruments, CA, USA) at the coordinates: AP=-0.37 mm; 
ML=+1.00 mm; DV=-1.5 mm with respect to bregma. A cannula was mounted to the 
skull with medical grade superglue (Loctite 454). A paired dummy was inserted into the 
guide cannula to prevent clogging (Plastics One; C315DCS-5-SPC, cut to completely fill 
the guide cannula). After the surgery, all mice received one-time intraperitoneal injection 
of buprenorphine (0.1mg/kg) and sterile saline (0.5 ml) for analgesia and rehydration 
respectively. More injections were given based on symptoms of pain and discomfort 
during recovery. Mice were allowed to recover from the surgery for at least 5 days before 
i.c.v. injections and behavioral testing. Implanted cannulas and animals were monitored 
on a daily basis.
2.1.4 Intracerebroventricular Injection
The 7PA2 CM, 17-AAG, OS47720 or vehicle [Chinese Hamster Ovary (CHO) 
CM for 7PA2 CM or 100% DMSO for 17-AAG and OS47720] alone, was administered 
??????????????????????????? ?????????????????????????????????????-AAG compound, or 
vehicle, was injected using a Hamilton syringe with a 27-gauge needle (Reno, NV, USA) 
?????????????????????????????????????????canula after removal of the dummy cap.
2.1.5 Intra-hippocampal CA1 Viral Microinjection
Intra-hippocampal CA1 injection of viruses was similar to cannulation. Instead of 
implanting cannulas, a KOPF microinjection unit (Model#: 5000) was used to inject 1 μl 
of AAV viruses into each of the CA1 region at the coordinates:  AP=-2 mm; ML=+1.5 
mm; DV=-1.75 mm with respect to bregma, with a speed of 0.2 μl/min for 5 minutes. 
Syringes (27-gauge needle) will be remained for an additional 3 min for drug diffusion. 
Virus-injected mice were housed for 3 weeks before tests to let the virus reach expression 
peak. In mice with both i.c.v. cannulation and intra-hippocampal CA1 microinjection, 
both surgical procedures were performed at the same time. Virus expression peak was 
determined by examining expression of EGFP at 1, 2, 3 and 4 weeks by sectioning brain 
slices (10-15 μm) after injection.
2.1.6 Compound Administration
The solvent used for OS47720 administration consisted of 6% dimethylacetamide 
(DMA), 5% Tween-80 in sterile H2O. The drug compound was injected through i.p. 
twice a week for the first 4 weeks, then three times a week until the end of study. 
Treatment started at 9-months Tg2576 mice and lasted for 3 months, or at 12-months 
Tg2576 mice and lasted for 6 months.
24
2.1.7 Behavioral Tests
2.1.7.1 Contextual Fear Conditioning. The Contextual fear conditioning test 
was conducted as previous described (Chen et al., 2014; Kittelberger et al., 2012). 
Briefly, mice were placed in a rectangular box with steel walls and a steel grid floor (30 L 
x 30 W x 25 H, cm) and video captured by overhead cameras of the four-chamber fear 
conditioning system (Coulbourn Instruments LLC). Fear acquisition was performed on 
Day 1 and contextual fear retention (24, 48 and 72 h) was performed on Day 2-4. During 
fear acquisition, three minutes baseline recording was given followed by a 20 s tone (2.8 
kHz, 82 dB) and a 2 s footshock (0.7 mA). One minute of recording was taken before the 
second similar tone-shock stimulus (a total of two presentations of the tone-shock 
pairing). Mice were recorded for another 1 min till the end. During contextual fear 
retention test, three minutes of recording was performed. Time intervals analyzed for the 
fear acquisition are as follows: minute 1 (m1): 0–60 s; minute 2 (m2): 60–120 s, minute 3 
(m3): 120–180 s; tone 1 (t1): 180–200 s; inter-tone interval (iti): 200–260 s; tone 2 (t2): 
260–280 s and end: 280–340 s. Time interval analyzed for the context fear retention is 
context from 60 to 180 s. Freezing percentage was analyzed by FreezeFrame software 
(Coulbourn Instruments LLC). A higher freezing percentage in contextual retrieval test 
reflects better memory.
2.1.7.2 Open Field Test. Each animal was individually placed in a novel open-
field arena (47 L × 37 W × 20 H, cm; 900 lux at the center; Accuscan Instruments) for 10 
min while being recorded by an overhead camera. Total locomotor activity was measured 
by beam breaks of the equipped 16 infrared beams. The footage was then analyzed by an 
automated tracking system (EthoVision XT software). The time spent in the center (25% 
of the field) was measured as a potential indicator for anxiolytic behavior.
2.1.7.3 Open-field Locomotor Activity. Exploratory locomotor activity was 
measured in an open field measuring 27 x 27 cm. Infrared beams and detectors 
automatically record movement in the open field. A 10-min session was given, in which 
the mouse was placed in the activity monitor and removed 10 min later. No discrete 
stimuli or motivators were applied, and there were no imposed contingencies to 
manipulate behavior. Total distance travelled was recorded as locomotor activity.
2.1.7.4 Elevated Plus Maze. The elevated plus maze (EPM) apparatus is a "+"-
shaped maze with two facing open arms, two facing closed arms and a center area 
(arm/wall sizes: 50 L × 10 W × 30 H, cm; Runway height from floor: 55 cm). Each 
mouse was allowed to freely explore the maze for 5 min. The preference for being in 
open arms over closed arms (expressed as a percentage of time spent in the open arms) 
was calculated to measure anxiety-like behavior.
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2.1.7.5 Novel Object Recognition. The task was conducted in an open arena (47 
L × 37 W × 20 H) with 2 objects in HSF1 heterozygous mice. During habituation (day 1), 
mice were allowed to freely explore the arena. On day 2, mice were exposed to 2 
identical objects (red cubes) placed in the center of the field. On day 3, 1 object was 
placed by another novel object (blue triangle). Each test lasted for 10 minutes. Time spent 
in exploring each object was recorded. Exploration time and discrimination index (= time 
spent in novel object / total exploration time x 100%) were calculated.
2.1.7.6 Cross Maze. Spontaneous alternation rates were assessed using a cross-
maze. Cross maze was conducted in a “+”-shaped maze with four white and opaque 
plastic arms with walls (arm/wall sizes: 50 L × 10 W × 30 H, cm). Animals were 
introduced from a fixed entry located in one of the four arms, and were allowed to freely 
explore four arms for 5 min. An alternation is defined as going into each of the four arms 
without repeating an arm. The number of alternations is then divided by the number of 
arm choices minus three to yield the alternation rate, which is a measure of working 
memory. 
2.1.7.7 Morris Water Maze. Morris water maze (MWM) test was conducted in a 
118-cm diameter round tank, filled with 25 °C opaque water using non-toxic white 
tempera paint (Crayola). During the test, mice were first trained to learn swimming and to 
find cued (visible by a black acrylic ball 30 cm above the platform) escape platform (10 
cm diameter; 0.5 cm above water surface) for 3 days, then underwent 10 days of hidden 
platform session (0.5 cm below water surface) and 1 additional day of probe trial session 
(platform removed). Two days of rest were given before mice went to hidden platform 
session. During the hidden platform session, swimming path and distance was recorded 
and calculated as measures of spatial and learning memory. During the probe trial 
session, hidden platform was removed. Platform crossings and time spent in a 40-cm 
zone centered on the former platform location were recorded as measures of spatial 
memory.
2.1.8 Perfusion and Fixation for Histology
For each surgery, we set up a perfusion syringe and attached a perfusion set with 
perfusion needle. Surgical scissors, forceps and clamps were prepared sterile with 
autoclave. 15% isoflurane (in mineral oil) was given to the animal. Once the animal was 
under anesthesia, we placed it on the operating pan with its back down. We used some 
tape to hold the appendages so that the animal was securely fixed. The pinch-response 
method was used to determine depth of anesthesia. An incision with scalpel was made 
through abdomen the length of the diaphragm. With sharp scissors we cut through the 
connective tissue at the bottom of diaphragm to allow access to rib cage. With large 
scissors, we cut through ribs just left of the rib cage midline. One center or two end 
horizontal cuts were made through the rib cage to open up the thoracic cavity. Clamp 
open to expose heart and provide drainage for blood and fluids. While holding heart 
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steady with forceps (it should still be beating), needle was inserted directly into 
protrusion of left ventricle to extend straight up about 4 mm. Needle position was secured 
by clamping in place near the point of entry. A steady flow of around 20 ml/min of PBS 
was manually injected. A cut in atrium was made with sharp scissors, and solution was 
flowing freely. If fluid was not flowing freely or was coming from animal’s nostrils or 
mouth, the needle was repositioned. When blood had been cleared from body, solution 
was changed to 4 percent paraformaldehyde (PFA) solution (30-60ml/mouse). Perfusion 
was almost complete when spontaneous movement (formalin dance) and lightened color 
of the liver were observed. The perfusion was stopped and the brain and other organs of 
body were collected. Tissues were placed in vials containing the same fixation and fix for 
another 2 more hours on ice or at 4 degree before proceeding to dehydration and 
embedding.
2.2 Biochemical Studies
2.2.1 Primary Cell Culture
Primary cortical and hippocampal neurons were isolated and purified from E17 
embryos of Sprague Dawley (SD) rats. Isolated primary neurons were either plated onto 
cover slips at a low density of 1 × 104 per well in 24-well plates for staining, or plated 
onto 6-well plates at a density of 6 × 105 per well, and 100 mm dishes at a density of 3 × 
106 per dish for Western Blot analysis. All plates were pre-coated with poly-D-lysine 
??????????????????????????????????????????????????-free Neurobasal medium (Invitrogen) 
with 2% B27 supplement (Invitrogen).
2.2.2 Immunocytochemistry and Dendritic Spine Quantification
Rat hippocampal neurons were cultured for 21 days at low density were fixed by 
4% PFA, permeabilized by 0.1% Triton X-100, and immuno-stained for synaptic proteins 
and visualized using a confocal fluorescence microscope. Anti-PSD95 (1:100; Santa Cruz 
Biotechnology), anti-Synapsin I (1:200; Cell signaling) antibodies and DAPI (Roche) for 
nuclear staining were used. Synaptic clusters were calculated as the average number of 
????????????????????????????????????????????-YFP was used to infect neurons (DIV 14) 
for 7 days (DIV 21) to highlight dendritic spines of hippocampal neurons at low density. 
Dendritic spines of primary and secondary basilar dendrites were counted and analyzed. 
Images were captured under a confocal microscope (Olympus). 488 nm and 594 nm 
wavelengths were used. Fluorescent intensity was analyzed by ImageJ software (NIH). 
60x object magnification was used to acquire images. 
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2.2.3 Protein Analysis
Cells were lysed in ice-cold lysis RIPA buffer, consisting of 50 mM Tris-HCl pH 
8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and a 
mixture of protease and inhibitors (Thermo Scientific, Inc). The protein concentration of 
each sample was determined by using Micro BCA Protein Assay Kit (Thermo Scientific) 
and read by Multimode plate reader (Beckman Coulter DTX 880). Samples were 
prepared and separated on NuPAGETM 4–20% Tris glycine gel (Life Technology) and 
transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). Antibodies 
(Abs) were used as follows: rabbit anti-Hsp90, cHsp70, Hsp40, Hsp27, HSF1, PSD95, 
Synapsin I (1:1000; Cell Signaling); mouse anti-iHsp70 (1:1000; Enzo Life Sciences), 
rabbit anti-BDNF (1:500; Santa Cruz Biotechnology); mouse anti-?-actin (1:10000; 
Sigma-Aldrich), rabbit anti-Synaptophysin (1:2000; Chemicon/Millipore), and anti-
mouse IgG and anti-rabbit IgG horseradish peroxidase-conjugated Abs (1:5000; Sigma-
Aldrich). The membranes were washed three times for 15 min each with TBST 
containing 0.05% Tween 20 (pH 7.4) and incubated with horseradish peroxidase-
conjugated secondary antibodies in 5% skim milk for 1 hour at room temperature. After 
washing three times with TBST, immunoreactive bands were visualized by using ECL 
Plus (Thermo Scientific) chemiluminescence reagent.
2.2.4 Naturally Aecret?????-containing Conditioned Medium
???????????? ??????????????????????????????????????????????????????????
collected from cultures of 7PA2/CHO cells as previously reported (Walsh et al., 2002; Li 
et al., 2014). The 7PA2 cells are Chinese Hamster Ovary (CHO) cells which stably 
express human APP751 which contains a Val717Phe mutation (an APP isoform of 751 
???????????????????????? ???????????????????????????????????????????????????????
derived from the conditioned medium of 7PA2 cells. Briefly, 7PA2 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM, HyClone) with 10% characterized fetal 
bovine serum (FBS; HyClone, Inc) and 200 μg/ml G418 (Calbiochem, Inc) until 80% 
confluence. Cells were then washed with sterilized PBS and conditioned in 5 ml of B27-
free neurobasal medium (Invitrogen, Carlsbad, CA) for about 16 hr. Afterwards, 7PA2 
CM was removed and cleared of floating cells and debris by passage through a sterile 
0.22 μM filter (EMD Millipore, Inc). The control medium, called CHO CM, was derived
similarly from CHO cells cultured in DMEM containing 10% FBS and G418. Aliquots of 
????????????????????????????????????????????????????????????????????????????
with 2% B27 and 0.5 mM glutamine. CM was used at original concentration for lateral 
ventricle microinjection, and was diluted at 1:1 with respective neurobasal culture 
medium to treat neurons.
2.2.5 RNA Analysis (PCR and qRT-PCR)
Total RNA was extracted from cells by using Trizol reagent (Life Technology). 
The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to 
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synthesize the first strand cDNA from the samples with an equal amount of RNA, 
according to the manufacturer's instructions. Synthesized cDNAs were then amplified 
and analyzed on Real-Time PCR Systems (Invitrogen) using SYBR Green MasterMix (5 
Prime, Inc.). Primers used were listed in Table 2-1.
2.2.6 Histology and Immunohistochemistry
Mice were heart-perfused by saline and 4% paraformaldehyde (PFA), post-fixed 
in 4% PFA overnight as detailed above. Mouse brains were paraffin-embedded, sectioned 
????????????? ?????????????????????????????????????????????????????????????????????????
through 100% xylene and then passing through serial dilutions of ethanol (100, 95, and 
75%). Hematoxylin and Eosin (H&E) staining was performed and images were captured 
under a light microscope. For Optimal Cutting Temperature compound (OCT) 
embedding, perfused brains were cryoprotected by 30% sucrose infiltration and then 
?????????????????????????????????????????????????-HSF1 (1:100; cell signaling), anti-?-
Amyloid (clone 4G8; 1:100; Covance), anti-GFAP (1:1000; Sigma) and anti-Iba1 (1:500; 
Wako) antibody were used and nuclei were stained with DAPI. Goat anti-Rabbit IgG 
secondary antibody, Alexa Fluor® 594 conjugate and anti-mouse IgG sencondary 
antibody,  Alexa Fluor® 488 conjugate (Thermofisher Scientific) were used.
2.2.7 ????-???????????-42 ELISA
??????????????????????????????????????????? ????????????????????????????????
????????????????????????????????????????????????????????manufacture’s protocol, with 
additional guanidine HCl to extract insoluble amyloid from tissues. Hippocampal tissue 
was quickly removed on the ice plate. Tissue was kept frozen at -80c if not used 
immediately. Tissue was then homogenized in extraction buffer (with or without 
additional guanidine HCl) and was place at 4c for 3 h. A protease inhibitor cocktail with 
AEBSF was added to inactive serine protease. The homogenate was centrifuged at 13,200 
rpm at 4 °C for 15 min, and the supernatant was collected for further analysis according 
to instructions.
2.2.8 Liquid Chromatography–mass Spectrometry (LC-MS)
Sample preparation. Brain tissues were collected at 1, 2, 6, and 24 hours 
following i.p. administration of the compound. The brain samples (~250 mg/mouse) were 
collected and homogenized after the addition of 100 μl de-ionized water. The compounds 
in the brain homogenates were extracted with 0.9 ml acetonitrile and cooled on ice for 20 
min. The supernatants (700 μl) were transferred to a new vial, centrifuged, and dried 
under N2. The dry samples were reconstituted into 140 μl of acetonitrile, mixed 
thoroughly, and centrifuged, the supernatant were used for LC-MS/MS analysis.
Analytical method. LC-MS/MS analysis was performed on an API-4500 triple-
quadrupole system (AB Sciex, Foster City, CA) with a Turbo V ESI ion source. The 
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Table 2-1 List of Primers.
Gene name (coding protein) Forward/Reverse Sequences (5’?3’)
DLG4 (PSD95) + gggacagcctttcctactacc
- agatctgcgcaaaagtcctg
SYN1 (Syn I) + gctgaagcagcagacctga
- ttcactggtatgaatcactgctg
SYP (Synaptophysin) + cactctgtgcccaagtatgg
- gctgtaggctggagatggag
BDNF + gtcacagcggcagataa
- gaccttttcaaggactgtgacc
GAPDH + gcaaattcaacggcacag
- ctcgctcctggaagatgg
Notes: List of primers used for qRT-PCR. All primers are listed from 5’ to 3’.
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spraying needle voltage was set as 5.5 kV for positive mode. Curtain gas was set at 10 psi, 
drying gas was set to 20 psi, nebulizing gas was set at 20 psi, and CAD gas was set at 7 
psi. The probe heater temperature was set at 400°C. Data acquisition and quantitative 
processing were accomplished by the Analyst software, version 1.6.1 (AB Sciex, Foster 
??????????????????????????????????????????????????????????????????????????????????
????????????? ????????????????? ???????????????? ?????????????? ???????????????
(positive mode), was used to obtain the most sensitive signals. Chromatographic 
separation of the analytes was performed using a Luna PFP column (50×2.0 mm i.d, 3.0 
???????????????????????????????????????????????????????????????????????????????????
elution. Mobile phase A: 0.01% formic acid in water; B: 0.01% formic acid in methanol. 
0-0.5 min: 2% B, 0.5-0.6 min: 2-98% B; 0.6-4 min: 98% B; 4-4.3 min: 98-2% B; 4.3-5.0
min: 2% B. The flow rate was set to 0.3 ml/min. 
2.3 Materials
2.3.1 Reagents 
OS47720 was gifted from Oncosynerge. Inc via collaboration. KRIBB11 was 
purchased from EMD Millipore. Hematoxylin and eosin, 17-AAG, Rp-cAMPs, H89, 
U0216, KN92, KN93 were purchased from Sigma-Aldrich. Geldanamycin (GA), 17-
DMAG, LY294002 were purchased from LC labs. 
2.3.2 Antibodies
17-??????????????????????????-actin were from Sigma-Aldrich. Antibodies 
against HSF1, Hsp90, Hsp70, Hsp40, Hsp27, PSD95, synapsin I, AKT, p-AKT, Rab 3a, 
SNAP25, SAP97, and CaMKII were from Cell Signaling Technology. BDNF antibody 
was from Santa Cruz Biotech. Alexa Fluor-conjugated antibodies were from Invitrogen. 
Antibody against synaptophysin was purchased from EMD Millipore. Goat anti-Rabbit 
IgG secondary antibody, Alexa Fluor® 594 conjugate and anti-mouse IgG sencondary
antibody,  Alexa Fluor® 488 conjugate were purchased from Thermofisher Scientific.
2.3.3 Viruses
AAVH-BH (AAV1/H-BH) overexpressing constitutive form of HSF1 (6.11x1012 
viral genomes/mL) and control AAVYFP (AAV1/YFP; 2.64×1012 vg/ml) was gifted 
from Dr. Deborah Young, The University of Auckland, Auckland, New Zealand. 
Construct of shRNAhsf1 was designed by Dr. Yueqiang Xue in Dr. Liao’s lab using the 
following sequence 5’-GCCCAAGTACTTCAAGCACAA-3’. AAVshRNAhsf1 
(AAV2/5CMVeGFPhU6shRNAhsf1) was packaged at Viral Vector Core Facility, 
University of Iowa at the titers of 1x1012 vg/ml.
31
2.4 Statistics
All statistical analysis was performed by Student's t-test for two groups’ 
comparison, or one way ANOVA followed by Tukey’s post hoc test for three or more 
groups’ comparison. Data are presented by means ± SEM. The asterisks indicate 
significant difference versus control as follows: *P < 0.05; **P < 0.01; and ***P < 0.001.
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CHAPTER 3.   17-AAG’S NEUROPROTECTION AGAINST A? TOXICITY
3.1 Introduction
17-AAG is an immediate GA derivative that has been widely investigated for its 
potential therapeutic effect on various cancers by targeting Hsp90 complex inhibition. It 
is the first-in-class Hsp90 inhibitor selected by the Cancer Therapy Evaluation Program 
(CTEP) of the National Cancer Institute (NCI) for clinic studies in cancer. As HSP90 
inhibitors, GA and its derivative analog 17-AAG initiate a heat shock-like response and 
the response was found in multiple cell types, among which most of them were cell lines. 
Investigations on 17-AAG provided a proof of concept of targeting Hsp90 inhibition in 
cancer treatment (Gorska et al., 2012; Jhaveri and Modi, 2012). Several clinic trials had 
been conducted to determine its safety profile and dosing strategy. Phase I trial of 17-
AAG in patients with advanced cancer (mainly breast and prostate cancers) revealed 
schedule-dependent toxicity and suggested an intermittent dosing strategy (Goetz et al., 
2005). Pharmacokinetic and pharmacodynamic studies of 17-AAG demonstrated the dose 
level 450 mg/m2/week or 40 mg/m2 daily for 5 days every 3 weeks had desirable clinic 
activity (Banerji et al., 2005; Grem et al., 2005). A phase II trial in patients with prostate 
cancer showed 17-AAG had no activity with regard to the prostate-specific antigen (PSA)
response but with a severe grade 3 fatigue (Heath et al., 2008). 
Besides the most studied area targeting cancer disease, 17-AAG also exhibited a 
great potential in treating neurodegeneration. In 2005, 17-AAG was discovered to be 
neuroprotective in ameliorating polyglutamine-mediated motor neuron degeneration. In 
cultured SH-SY5Y cells, treatment with 17-AAG induced expression of heat shock 
proteins. Intraperitoneal injection of 17-AAG was found to degrade polyglutamine-
expanded mutant Androgen Receptor (AR), which is a pathogenic gene product in spinal 
and bulbar muscular atrophy (SBMA), associated with Hsp70 induction in the spinal cord. 
17-AAG ameliorated phenotypic expression on SBMA mice (Waza et al., 2005; Waza et 
al., 2006). In tau pathology, Dou et al. showed that GA and 17-AAG reduced tau 
phosphorylation and its abnormal aggregation through inhibition of the Raf-MEK-ERK 
pathway (Dou et al., 2005). Luo et al. revealed the amelioration in AD mice model 
(JNPL3 line) with tau pathology improvement after 17-AAG treatment (Luo et al., 2007). 
In a recent comparison study, treatment of 17-AAG significantly reduced NFT area in 
?????? ?????????????????????????????????? ?????????????????????????????????????
injections (5 and 25 mg/kg) for 3 months (Ho et al., 2013). Though the result is not 
convincing enough due to the known limited CNS-permeability of 17-AAG, it suggest 
the great potential of 17-AAG in treating AD. 
Tg2576 mice have been recognized as a classic mouse model of AD. They 
overexpress a mutant form of APP (isoform 695) bearing the Swedish mutation 
(KM670/671NL). Tr????????? ????????????????????????????? ??????????????????????????
has been extensively characterized in this model, as reported that impaired learning at a 
spatial task, working memory and progressive impairment at 12 months (Hsiao et al., 
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1996; Westerman et al., 2002). In the current study, Tg2576 mice were selected as AD 
mouse model.
For all the past studies of 17-AAG on neurodegeneration, the major mechanism 
relied either on inducing heat shock proteins or clearing disease pathology related 
proteins. In the current study, since AD is also a synapse disease, as a proof of concept, 
we provided evidence of 17-AAG showing synaptic protection by improving synaptic 
structure, activity and function.
3.2 Results
3.2.1 17-AAG Induces Rapid and Sustained Expression of HSPs and Synaptic 
Proteins in Neurons
In the current study, treatment with 17-AAG was found to rapidly induce HSF1 
activation in rat primary cortical neurons (14 DIV), as evidenced by its nuclear 
translocation (Figure 3-1A). Similar to cancer cells, 17-AAG treatment also led to rapid 
induction of multiple HSPs in neurons, in particular inducible iHsp70 and Hsp27 (Figure 
3-1B), with a sustained effect lasting for at least 24 h achieved at 100–200 nM 
?????????????????????????????????????????????????d cytotoxicity in neurons. Hsp40 
expression was also increased, to a lesser degree. No change was found in the constitutive 
form of Hsp70 (cHsp70). Mechanistically, 17-AAG only disrupts protein interactions 
between Hsp90 and its clients, therefore it does not change the amount of Hsp90 itself. 
The activity of the Hsp90 inhibitor was further confirmed by its ability to disrupt a major 
Hsp90 client protein, protein kinase B/AKT in neurons (Figure 3-1B).
Interestingly, using Western blot it was found that 17-AAG caused an increase in the 
expression of select presynaptic and postsynaptic proteins (synapsin I, synaptophysin, 
and PSD95), beginning 1 h after treatment and reaching peaks within 3 h (Figure 3-1C). 
This effect appears to be specific to certain synaptic proteins, since the expression of two 
other PDZ-containing scaffolding proteins, SNAP25 and SAP97, as well as presynaptic 
Rab3a and CaMKII (the most abundant postsynaptic protein) were not affected by 17-
AAG (Figure 3-1C). 
To get further evidence of 17-AAG’s effect on established proteins localized at 
synaptic dendrites, cultured rat hippocampal neurons (21 DIV) were used for 
??????????????????????????????????????????????????????????????????????????????????
expresses APP carrying the V717F mutation This cell line has been fully characterized by 
Walsh et al. (Walsh et al., 2002). 7PA2 cells secrete high levels of monomeric and small 
?????????????????????????????????????????????????????????????????????????????????????
been proven to be a toxic species to brain cells (Mattson et al., 2001; Hashimoto et al., 
???????????????????????????????????????????????????????????1 nM), which is equivalent 
to concentrations in human AD brains, can rapidly impair the normal morphology of 
dendritic spine and uncouple dendritic spines from their nerve terminus (Calabrese et al., 
2007; Shankar and Walsh, 2009). By using two-fold diluted conditioned media collected
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Figure 3-1 17-AAG Induces HSF1 Nuclear Translocation, HSPs and Synaptic 
Proteins.
Modified with permission. Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, Zhu LQ, 
Heldt SA, Xu H, Liao FF. (2014). Hsp90 chaperone inhibitor 17-?????????????????-
induced synaptic toxicity and memory impairment. J Neurosci. 34, 2464-2470.
(A) Subcellular localization of HSF1 was observed by conducting immunocytochemistry 
on cultured primary hippocampal neurons (14-21 DIV, >95% purity) 0.5 h after treatment 
of 200nM 17-AAG, using anti-HSF1 antibody (green) and DAPI (blue). White arrows 
indicate cytoplasmic HSF1 (green) in the control neurons and overlap between HSF1 
signaling (green) with DAPI (blue) in the nuclei in the majority of treated neurons. 
Representative images are shown from 6 independent experiments with objective 
magnification set at 25× during image capturing. Scale bar is 20 μm. (B) Western blot 
analysis of HSPs as well as AKT, p-AKT levels after treatment with 200 nM of 17-AAG. 
(C) Induction of both presynaptic and postsynaptic protein expression by 17-AAG, as 
determined by Western blot analysis. Syn I, synapsin I. Results are representative 
Western blots of 10 experiments. (D) Immunocytochemistry for PSD95 and synapsin I in 
mature neurons (21 DIV) 4 h after exposure to 17-AAG (200 nM) with objective 
magnification at 60×. Scale bar is 5 μm.
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from ??????????????????????????????????????????????????????????????????????????????????
In matured neurons (21 DIV), PSD95 and synapsin I protein levels were both 
??????????????????????????????????????????????????????????????????????????????????????????
17-AAG co-treatment (Figure 3-1D). Confocal microscopic analysis of the double-
labeled immunofluorescent stained neurons demonstrated that these two vesicle-related 
antigens were closely colocalized in neuronal dendrites, showing numerous puncta of 
synapsin I and PSD95 (Figure 3-1D). Consistent with the Western blot data, 
immunocytochemical results confirmed that 17-AAG not only prevented the A 
?????????????????-induced decrease in individual protein expression, but also rescued 
functional synapses, as measured by PSD95 clusters and proximate PSD95-synapsin I 
cluster complexes.
3.2.2 17-AAG Protects Synaptic Structure A?????????
??-induced loss of dendritic spine was further examined, as well as the effect of 
17-AAG on spines by the co-treatment of 17-??????????? which were determined by 
quantification of dendritic spine density. Dendritic spines represent the structure in the 
CNS that allows for multiple inputs and is the highly dynamic site of excitatory synapses. 
The protective effect of 17-AAG was observed at 24 h (Figure 3-2A and B). Strikingly, 
17-AAG treatment itself slightly increased the number of dendritic spines, and co-
???????????????????????????????????????-induced synaptic structure impairment. Because 
dendritic spines are the primary site of glutamate receptors and synaptic transmission, our 
findings regarding 17-???????????????????????????????????????????-induced reduction in 
mature spine density suggest a role for 17-??????????????????????????????????-impaired 
synaptic transmission. Together with previous results on synaptic protein, these results 
strongly suggest that 17-AAG induces formation of active synapses which leads to 
improved synaptic transmission as the clusters of these presynaptic and postsynaptic 
proteins represent functionally active synaptic zones.
3.2.3 17-AAG Transcriptionally Upregulates Synaptic Proteins
Because 17-AAG-induced expression of PSD95 and synapsin I proteins occurs 
within the first 2 h, the responsible mechanism is more likely through transcriptional 
activation. In cultured rat hippocampal neurons (21 DIV), qRT-PCR was used to examine 
mRNA levels of select synaptic proteins after 17-AAG treatment at various time points. 
Indeed, 17-AAG rapidly increased the mRNA levels of PSD95, synapsin I, and 
synaptophysin by approximately two-fold, as determined as early as 0.5 h after treatment 
by qRT-PCR (Figure 3-3).
3.2.4 17-AAG Prevents Memory Loss I????????????
To test whether 17-???????????????? ??????????????????????????????????????
model in adult B6 mice (4-6 months of age) was established, in which 7PA2 cell-secreted 
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Figure 3-2 17-AAG Protects Neurons f??????-induced Dendritic Spine Loss.
Modified with permission. Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, Zhu LQ, 
Heldt SA, Xu H, Liao FF. (2014). Hsp90 chaperone inhibitor 17-?????????????????-
induced synaptic toxicity and memory impairment. J Neurosci. 34, 2464-2470.
(A) Representative confocal images of dendritic spines on cultured neurons infected with 
AAV1-YFP for 7 days (7-14 DIV), with indicated treatment for 24 hours. Scale bar is 5 
μm. (B) Quantification of dendritic spines on 10 fields per slide. N=5. One-way ANOVA 
was performed followed by Tukey’s post hoc test. *P < 0.05. Data are represented as 
mean ± SEM.
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Figure 3-3 17-AAG Activates Transcription of Select Synaptic Genes.
Modified with permission. Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, Zhu LQ, 
Heldt SA, Xu H, Liao FF. (2014). Hsp90 chaperone inhibitor 17-?????????????????-
induced synaptic toxicity and memory impairment. J Neurosci. 34, 2464-2470.
17-AAG upregulates the transcriptional levels of PSD95, synapsin I, and synaptophysin, 
as determined by qRT-PCR at different time points up to 24 h. *P < 0.05. Two-way 
student’s t-test was performed. N=3. Data are represented as mean ± SEM.
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?????????????????????????? ????????????????????????????????ntricles using implanted 
cannulas. Contextual conditioned freezing memory was evaluated by the freezing 
percentage during the contextual fear conditioning test. A higher freezing percentage 
reflects better memory. During Day 1, mice received the first injection (injection 1) 1h 
before fear training. The second injection was given 3 h after the training. On Day 2, a 
third injection was given 1h before the context retrieval test (Figure 3-4A).  The 
contextual fear retention (contextual retrieval) tests were performed from Day 2 to Day 5 
at 24 h interval. These results showed that contextual conditioned freezing memory was 
????????????????????????????????-injection of 17-AAG (2 μl/100 μM) improved 
contextual conditioned freezing memory at the 72 h time point, almost to the level of the 
control group (Figure 3-4B and C). Biochemical analyses were conducted after the 
behavior test. Both PSD95 and mature Brain-derived neurotrophic factor (BDNF) were 
completely rescued by co-??????????????????????-AAG (Figure 3-4D), according to 
quantification of Western blot analysis (Figure 3-4E and F).
3.3 Summary
In this first part, we discovered that in vitro treatment of 17-AAG promoted HSF1 
nuclear translocation and induced a heat shock-like response in cultured primary neurons, 
associated with an increase of several select synaptic proteins, such as PSD95, synapsin I, 
and synaptophysin. This was confirmed by both Western blot analysis and 
immunofluorescent staining. qRT-PCR showed regulation at the transcriptional level. 17-
?????????????????????????????????????????????????????????????????????????????????????????
neuronal structure by increasing dendritic spines. 
Targeting Hsp90 inhibition by inhibitors has yet to be studied using in vivo AD
models. The current study further tested 17-???????????????????????????????? ?????
model and examined memory in contextual fear conditioning test. Stereotaxic 
microinjection of 17-AAG through implanted cannula rescued memory impairment 
???????????????????????????????????????????????????????????????????????????????????
after 17-AAG microinjection.
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Figure 3-4 17-AAG Prevents Memory Loss I?????????????In vivo.
Modified with permission. Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, Zhu LQ, 
Heldt SA, Xu H, Liao FF. (2014). Hsp90 chaperone inhibitor 17-?????????????????-
induced synaptic toxicity and memory impairment. J Neurosci. 34, 2464-2470.
(A) Experimental design of the contextual fear conditioning assay to test the effect of 17-
?????????-induced impairment of contextual conditioned freezing memory. 17-AAG (2 
???????????????? ????????????????????????????????????????????????????????????????????????
cannula. (B) Fear acquisition during the first day training. (C) Recorded contextual fear 
retention. *p<0.05 N=14 animals each group. (D) Protein expression levels of PSD95 and 
BDNF from the mouse hippocampi after the fear conditioning experiment. 
Representative images from Western blot are shown on 4 of 14 mice each group. (E-F) 
Quantification of the Western blot images by densitometry. One-way ANOVA with 
Tukey’s post hoc test. *P < 0.05 and **P < 0.01. N=14 animals each group. Data are 
represented as mean ± SEM. 
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CHAPTER 4.   EVALUATION OF THERAPEUTIC EFFECT OF OS47720
4.1 Introduction
The development of more tolerable Hsp90 inhibitors was promoted by the 
investigation of potential therapeutics for cancers. Radicicol is a macrocyclic antifungal 
natural compound isolated from Monocillium Nordinii and Monosporium Bonorden 
(Delmotte and Delmottte-Plauqe, 1953) with unrelated structure to Geldanamycin (GA), 
and which competes with GA and specifically binds to the Hsp90 complex at the N-
terminus domain. Radicicol represents another category of Hsp90 inhibitors with the 
feature of non-benzoquinone ansamycine structure. Radicicol does not deplete Hsp90 
from cells, but rather promote synthesis as well as the stability of Hsp90, similar to the 
stress response (Schulte et al., 1998). Radicicol exhibited antitumor activity in vitro, but 
not in vivo because there are some inherent structural limitations (Soga et al., 2003; Pearl 
et al., 2008). Later efforts have been prompted to generate new radicicol derivatives due 
to this unstable structure nature of the compound. Benzoquinone ansamycines and its 
derivatives were reported to display liver and renal toxicity (Supko et al., 1995; Page et 
al., 1997), however the radicicol oxime derivative KF25706 had no liver and renal 
toxicity at the dose effective in tumor inhibition (100 mg/kg twice daily for 5 consecutive 
days) (Soga et al., 1999). Other than KF25706, another novel small molecule series based 
on radicicol, was designed, synthesized by NexGeneix Pharmaceuticals Inc. (now 
acquired by Oncosynergy, Inc) in 2009, with the lead compounds of this series being 
OS47701 (former name NXD30001) and OS47720 (former name NXD30020). OS47701 
can cross the blood-brain barrier (BBB) (Zhu et al., 2010), so it can be useful for in vivo
efficacy tests. Compared with OS47701, OS47720 appears to be of slightly better 
potency in induction of heat shock proteins (iHSP70) in cultured primary neurons tested 
by a labmate in Dr. Liao’s lab. 
Besides the poor bioavailability of radicicol itself, radicicol derivatives have been 
synthesized to improve in vivo efficacy (Proisy et al., 2006) in cancer research. Shiotsu et 
al. tested KF25706 and KF58333 which are both novel oxime derivatives of radicicol. 
Therapeutic potential for the treatment of chronic myelogenous leukemia (CML) was 
observed by systemic administration of the compound KF58333 in mice. The underlying 
mechanism was found to work through the destabilization of Hsp90 client proteins (Bcr-
Abl) (Soga et al., 1999; Shiotsu et al., 2000). More research confirmed the antitumor 
effect in both in vivo and in vitro (Soga et al., 2001; Soga et al., 2003; Ikuina et al., 2003). 
However, little or no work has been done in further testing their antitumor effect due to 
the lack of in vivo efficacy. Until recently, the novel radicicol derivative OS47701
potently inhibited glioblastoma multiforme (GBM) cell proliferation in vitro by
degrading many of the key effectors during GBM pathogenesis. In an epidermal growth 
factor receptor (EGFR) driven genetically engineered mouse model of GBM, OS47701 
treatment induced GBM tumor regression and enhanced the general survival rate (Zhu et 
al., 2010). 
Other than cancer, radicicol and its derivatives were also introduced in treating
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neurodegeneration. It was reported that in cultured dorsal root ganglion (DRG) neurons, 
low concentrations of radicicol promoted neurite outgrowth and neuronal survival of 
embryonic sensory and sympathetic neurons, but radicicol at higher concentration 
provided less effect (Sano, 2001). This implied a potential of applying radicicol in 
neurodegenerative diseases. Radicicol treatment was able to induce a heat shock-like 
response and delayed aggregation of polyglutamine (polyQ) repeats in organotypic 
hippocampal cultured slice from R6/2 mice (HD mice model) (Hay et al., 2004). More 
recently, NXD30001 showed its potency in treating an ALS mouse model with motor 
neuron degeneration. CNS-permeability was confirmed by the quick distribution to brain 
and spinal cord. In vivo treatment of NXD30001 in mice prevented aggregation of 
mutated proteins, fragmentation in mitochondria and neuronal death (Zhu et al., 2010).
In studies discussed in previous chapter, we successfully proved the concept of 
using an Hsp90 inhibitor in treating AD, mainly through boosting synaptic activity and 
function. In this chapter, we discuss extensive testing the novel new HS90 inhibitor 
OS47720 for its effect in both in vitro and in vivo AD models. We examined whether 
OS47720 can affect synaptic activity and whether long-term OS47720 treatment can 
??????????????????? ????????????????????? ????
4.2 Results
4.2.1 Toxicity Study of OS47720
To study the toxicity of the OS47720 compound, it was compared to 
geldanamycin (GA) and the safer compound 17-AAG as the “gold standard” used in 
numerous clinical cancer trials. The chemical structures of these compounds are shown in 
Figure 4-1A. GA has long been recognized to have severe hepatotoxicity (Supko et al., 
1995; Amin et al., 2005). It was also reported that GA could induce apoptosis in 
erythrocytes even under physiological concentrations (Jilani et al., 2013). Because of 
these side effects, several analogues had been developed to reduce systemic toxicity, 
including 17-AAG and 17-DMAG [17-(2-dimethylaminoethyl)-amino-17-
desmethoxygeldanamycin]. 17-AAG had been proven to be much less toxic and more 
stable. These three compounds were selected for comparison of liver and kidney toxicity.
Compounds were injected i.p. at 100 mg/kg once daily in young adult B6 mouse 
(N=2). Solvent formula was modified based on a publication for NXD30001, OS47720’s 
previous generation (Zhu et al., 2010). Mice from the GA group died within 24h of the 
injection. This is consistent with all the previous reports (Supko et al., 1995; Amin et al., 
2005). During the first toxicity test, one mouse receiving 17-AAG injection was dead at 
the day 5 after 4 daily injections; another mouse appeared to be normal. Another two 
mice were used to test the toxicity of 17-AAG (N=4 total). On day 5, both of these mice 
were moribund. This indicates that 100 mg/kg is a sublethal dosage of 17-AAG. In
contrast, mice from the OS47720 group were normal in appearance and activity. In order
to see cellular changes under the treatments, livers and kidneys were embedded in
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Figure 4-1 Compounds’ Structures and Toxicity.
(A) Chemical structures of GA, 17-AAG, 17-DMAG, radicicol and OS47720 
(pochoxime C). (B) Representative images of whole liver morphology and H&E staining
(row 1 and 2); representative images of gross kidney morphology in paraffin embedded 
blocks and H&E staining. GA and 17-AAG treated mice exhibited dead fragmented 
hepatocytes (HPCs) and degeneration of the epithelial lining of the renal tubules (row 3 
and 4).
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paraffin blocks and hematoxylin and eosin (H&E) staining was performed. 
Hepatotoxicity and nephrotoxicity was evidenced by the presence of dead fragmented 
hepatocytes (HPCs) and degeneration of the epithelial lining of the renal tubules 
(representative images shown in Figure 4-1B).
4.2.2 OS47720 Induces HSPs and Synaptic Proteins in Neurons
To test if OS47720 compound works similarly as 17-AAG, OS47720 compound 
was tested in cultured primary hippocampal neurons. Immunofluorescence (IF) staining 
and confocal imaging revealed that OS47720 induced rapid HSF1 nuclear translocation, 
an effect which lasted for at least 24h evidenced by the appearance of increased HSF1 
granules (Figure 4-2A). Small (0.5-1.5 μM) and large granules (1.5-3 μM) were 
quantified respectively (Figure 4-2B, C and D).
Western blot analysis showed that OS47720 treatment (100 nM) induced iHsp70 
(inducible Hsp70) and Hsp40 protein expression (Figure 4-2E and F). Because the 
Hsp90 inhibitor only disrupted protein interactions between Hsp90 and its clients, it did 
not change the protein level of Hsp90 itself. Constitutive Hsp70 was also unchanged by 
OS47720 treatment (Figure 4-2E). OS47720 treatment induced a maximum increase of 
iHsp70 by 24h and the heat shock-like effect lasted for at least 72h. Besides the induction 
of iHsp70, other heat shock proteins such as Hsp40 and Hsp27 were also induced, 
however at somewhat earlier time-points (0.5h and 1h respectively). Consistent with the 
reported 17-AAG data (Chen et al., 2014), synaptic proteins such as PSD95 and BDNF 
were also upregulated by OS47720 treatment (Figure 4-2F), as further evidenced by 
quantification analysis (Figure 4-2G). These data demonstrated that OS47720 compound 
displayed a comparable effect to that of 17-AAG.
4.2.3 OS47720 Protects Synaptic Structures A?????????
???????????????????????????????????????????????????????????????????????????
with and without OS47720 co-treatment. PSD95 (green) and Syn I (red) double-
fluorescence staining were performed. Images were captured using a confocal 
microscope (Figure 4-3A). Consistent with the Western blot analysis data shown in 
Figure 4-2E and F, OS47720 treatment significantly increased expression of PSD95. 
Both presynaptic Syn I and postsynaptic PSD95 were greatly impaired ?????????????????
This impairment was partially rescued by the co-treatment with OS47720. PSD95 and 
???????????????????????????????????????????????????????????????????????????????????????
OS47720 (Figure 4-3B, C and D). 
To identify basic dendrites of neurons, AAV1-YFP was used to highlight neurons 
so neuronal dendrites could be visualized under a fluorescence microscope. Primary and 
secondary dendrites were captured and analyzed. Figure 4-3E shows the representative 
images of primary dendrites. Dendritic spines were promoted by OS47720 treatment 
??????????????????????????????????????????????????????????????????????????????????
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Figure 4-2 Nuclear Translocation of HSF1 Induced by OS47720 in Culture 
Mature Neurons.
(A) Subcellular localization of HSF1 was observed by conducting immunocytochemistry 
on cultured primary hippocampal neurons (21 DIV), using anti-HSF1 antibody (red) and 
DAPI (blue) in a time-course study. Scale bar is 10 μm. Histograms shows quantification 
of total (B), small (0.5-1.5 μM in diameter) (C) and large (1.5-3 μM in diameter) (D) 
granules per nucleus based on 6~9 randomly picked fields per slide from each treatment. 
N=4. One-way ANOVA was performed followed by Tukey’s post hoc test. All time 
points vs ctrl. *P < 0.05, **P < 0.01 and ***P < 0.001. (E-G) OS47720-induced HSPs 
and synaptic proteins: (E) Induction of HSPs on Western blot analysis by the treatment of 
100 nM OS47720 for 24 hours. (F)  Induction of HSPs and synaptic proteins by 100 nM 
of OS47720 treatment for up to 72 hours. (G) Statistical analysis of Western blot data 
???????????????-actin was based on 4 independent experiments. N=4. One-way ANOVA 
with Tukey’s post hoc test. All time points vs ctrl. *P < 0.05, **P < 0.01 and ***P <
0.001. Data are represented as mean ± SEM.
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Figure 4-3 OS47720 Exhibits Synaptic Protection A??????????Toxicity.
(A) Representative confocal images of immunofluorescence labeling of PSD95 and 
synapsin I, with indicated treatment for 24 hours. Scale bar is 5 μm. (B-D) Quantification 
of PSD95 and synapsin I clusters, as well as PSD95/Syn I merged clusters. N=4. (E) 
Representative confocal images of dendritic spines on cultured neurons transfected with 
AAV1-YFP for 7 days, with indicated treatment for 24 hours. Scale bar is 5 μm. (F) 
Quantification of dendritic spines on 10 fields per slide. N=5. One-way ANOVA with 
Tukey’s post hoc test. *P < 0.05, **P < 0.01 and ***P < 0.001. Data are represented as
mean ± SEM.
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???????????????????????????????????????????????????????????????Figure 4-3F.
4.2.4 Pharmacokinetics of OS47720  
As OS47720 compound is a new compound, there is no literature reporting its 
basic Pharmacokinetics and Pharmacodynamics, except the recent publication on its 
previous generation compound NXD30001 (Zhu et al., 2010). By using liquid 
chromatography–mass spectrometry (LC-MS), a single injection of OS47720 compound 
in young adult B6 mice at a dosage of 100mg/kg induced rapid brain accumulation within 
1h. Then the compound was gradually cleared from 2 h to 24 h. At 24 h, there is only a 
trace amount of OS47720 compound remaining in the brain. This data confirmed its 
CNS-permeability (Table 4-1) and is consistent with the published data on OS47701 
(Zhu et al., 2010).
4.2.5 Pharmacodynamics of OS47720
Mice received a single i.p. injection of OS47720 at 100mg/kg. Four tissue 
samples from the liver, skeletal muscle, spinal cord (lumbar section) and hippocampus 
(brain) were collected at different time points from 0.5h to 48h. The protein levels of 
iHsp70 and PSD95 were examined. The liver showed the greatest response to OS47720 
compound, as evidenced by the maximum increase of iHsp70 starting from 2h (Figure 
4-4A). The iHsp70 protein was most abundant in skeletal muscle, where the heat shock-
like response started as early as 0.5h after injection. There was no PSD95 protein 
expression in these two tissues. The hippocampus, the most relevant tissue to memory, 
also exhibited a good response to OS47720 compound, with iHsp70 starting to increase at 
6h and lasting for at least 48h. Less iHsp70 was detected in the lumbar spinal cord; 
however PSD95 levels in both tissues were significantly upregulated starting from 2h, 
particularly in the hippocampus where PSD95 is more enriched (Figure 4-4A). This is 
consistent with the finding that the hippocampus, the memory related region, was one of 
the main targets in brain.  
In addition to Western blot analysis, IF staining was conducted on the collected 
brain slices. Confocal imaging was performed using Z-scans at a 1 μm depth. Nuclear 
HSF1 (red) was mostly increased in the CA1 region as evidenced by increased 
fluorescence intensity, to a lesser extent in the CA3 region (Figure 4-4B), but not 
observed in other brain regions such as cerebral cortex. It is not known if the nuclear 
HSF1 represents transcriptionally active molecules in neurons.
In order to further investigate the heat shock-like response induced by the 
OS47720 compound, Hsp70-mPlum reporter mice were used, via collaboration with Dr. 
Anna M. Planas from Institute for Biomedical Research of Barcelona (de la Rosa et al., 
2013). mPlum transgenic mice are generated from an injection of an Hsp70-mPlum far-
red fluorescence vector with a genomic DNA sequence of the heat shock 70kDa Protein 
1B (Hspa1b) promoter into blastocyst. Young reporter mice received OS47720 at
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Table 4-1 Pharmacokinetics of OS47720.
Time 
point
Mouse ng/g Time 
point
Mouse ng/g Time 
point
Mouse ng/g Time 
point
Mouse ng/g
1h Mouse1 760.5 2h Mouse6 643.2 6h Mouse9 126.9 24h Mouse12 4.4
Mouse2 1016.2 Mouse7 308.2 Mouse10 92.1 Mouse13 2.5
Mouse3 1035.5 Mouse8 290.6 Mouse11 147.2 Mouse14 2.7
Mouse4 947.7 Mouse15 3.1
Mouse5 954.0
Mean
+
STD
942.8
+
108.8
414.0+
198.7
122.1+
27.9
3.2
+
0.9
Notes: OS47720 brain concentrations after single injection of OS47720 at 100mg/kg intraperitoneally. Brains were collect at four 
different time points (1h, 2h, 6h and 24h). N=3-5.
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Figure 4-4 Pharmacodynamics of OS47720.
(A) Mouse liver, skeletal muscle, lumbar spinal cord, and hippocampi were collected at 6 
different time points after i.p. injection of OS47720 at 100 mg/kg. Western blot analyses 
detecting inducible Hsp70 (iHsp70), PSD95, and GAPDH were performed. Histogram
below shows statistical analysis. n = 3. (B) Representative images of HSF1 
immunohistochemistry (red) of the four different regions and sub-regions of mouse brain 
(Hippocampal CA1-a, CA1-b, CA3 and cerebral cortex), with nuclei stained with DAPI 
(blue). Images were captured by a confocal microscope at 600× magnification. Scale bar 
is 50 μm. n = 3. One-way ANOVA was performed followed by Tukey’s Post hoc test, all 
groups vs Veh, *P < 0.05, **P < 0.01 and ***P < 0.001. Data are represented as mean ± 
SEM.
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100mg/kg through a single i.p. injection and tissues were collected at several time points 
following injection. Mice were perfused with 4% paraformaldehyde (PFA). Brains and 
livers were nfiltrated with 30% sucrose for cryoprotection, followed by embedding with 
OCT embedding. Z-scans were performed on the confocal microscope. Different sub-
regions within hippocampus are presented in Figure 4-5A. Enhanced far red signal was 
obtained in the CA1 and CA3 regions of mice receiving OS47720, which indicated the 
increase of iHsp70, the major target of activated HSF1. Liver showed the strongest 
response to OS47720 compound (Figure 4-5B), consistent with the protein changes 
shown by the previous Western blot analysis (Figure 4-4B), although the response was 
weaker than that in liver. Despite a relatively weak heat shock-like stress response, the 
induction of synaptic proteins is strong and long-lasting in hippocampi. These findings 
imply a potentially important role of enhanced HSF1-mediated regulation in 
hippocampus-mediated functions, such as learning and memory, in specific sub-regions 
within hippocampus.
In comparison to the more significant increase in nuclear HSF1 levels, iHsp70 
induction is relatively weak in hippocampal neurons compared to the liver. This indicates 
a weak heat shock like stress response in neurons when compared to other tissues, which 
can explain the particular vulnerability of neurons during neurodegeneration.
4.2.6 OS47720 Rescues Contextual Conditioned Freezing Memory Loss Induced 
?????
In order to test whether OS47720 could protect synaptic function and prevent 
??????????????? ?????????????????????????????????????????????????design for this acute 
model as in 17-AAG’s study in previous chapter was used (Figure 4-6A). In young 
???????? ??????????????????????????????? ???????????????????????????????
administered 5 days after daily OS47720 injection (ctrl group received vehicle injection), 
three times via i.c.v. injection through the implanted cannula at the indicated time points 
(Figure 4-6A). The acquisition of freezing behavior was recorded during the first day of 
training, and the contextual fear retention was recorded 24, 48 and 72 h later. As shown 
in Figure 4-6B, co-treatment of OS47720 significantly rescued contextual conditioned 
????????? ?????????????????????? ?????????????????????????????????????????????????????
levels of both PSD95 and BDNF were restored to the control level (Figure 4-6C and D). 
??????????????????????????????????????
4.2.7 Chronic OS47720 Treatment Did Not Change Either Anxiety or Locomotor 
Activity
OS47720 (100 mg/kg i.p. every two days for 3 months) was firstly tested on 
presymptomatic (early-stage) Tg2576 and littermate control mice starting from 9 months 
of age to 12 months of age. This dosage was determined based on a previous study (Zhu 
et al., 2010) and previous experiment in which the heat shock effect lasted for at least 
48hafter a single injection of OS47720, based on the PD data. Mice were divided into the 
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Figure 4-5 OS47720 Induces Hsp70 Protein Expression on Reporter Mice.
(A) Diagram indicates sub-regions of hippocampus. (B) mPlum-Hsp70 reporter mice 
received OS47720 intraperitoneally at 100 mg/kg. Brains and livers were perfused at 
different time points, OCT embedded, cryostat-sectioned (10 μM), and immunostained 
with anti-HSF1 antibody (red) and DAPI (blue). Figure shows representative images 
from confocal microscopy at 600 x magnification. Scale bar is 100 μm. 
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Figure 4-6 OS47720 Prevents Memory Loss I?????????????In vivo.
(A) Experimental design of the contextual fear conditioning test to test the effect of 
??????????????????-induced impairment of contextual conditioned freezing memory. (B) 
Freezing time (%) during fear acquisition (training) and fear retention (context retrieval) 
in contextual fear conditioning test. N=12. (C) Protein expression levels of PSD95 and 
mature BDNF from the mouse hippocampi after the experiment. Representative Western 
Blot images are shown on 4 of 12 mice each group. (D) Quantification of the Western 
blot images. One-way ANOVA with Tukey’s post hoc test. *P < 0.05. N =12 animals per 
group. Data are represented as mean ± SEM.
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following four groups: 1. NonTg2576-Vehicle group (NonTg-Veh); 2. NonTg2576-
OS47720 group (NonTg-OS47720); 3. Tg2576-Vehicle group (Tg-Veh); 4. Tg2576-
OS47720 group (NonTg-OS47720). There were 20 or 21 mice in each group with half 
males and half females. 
To test whether OS47720 affects basal locomotor activity and anxiety, the open 
field test and elevated plus maze were used.  Three parameters were evaluated in the open 
field including total activity (by beam breaks), distance travelled and time spent in the 
center. Open field test showed that Tg2576 mice had slightly less locomotor activity than 
littermate controls, whereas treatment of OS47720 increased locomotor activity slightly 
(Figure 4-7A, B and C), but these were not statistically significant results.
The elevated plus maze test was conducted to evaluate if OS47720 caused any 
anxiety-like behavior. The preference for being in open arms over closed arms (expressed 
as a percentage of time spent in the open arms) is calculated as a measure of anxiety-like 
behavior. There were no group difference on any measure of anxiety, including total arm 
entries, arm entries in closed and open arms (Figure 4-7D), and percentage of time spent 
on center, closed and open arms (Figure 4-7E). According to the analysis based on 
different sex, there was a small effect of sex on percentage of time spent on open arms 
such that female mice of all groups spent around 5% more time on open arms than male 
mice, and less time in the center. No sex difference in time spent in the closed arms was 
observed. This small difference should not affect performance on the cognitive tasks, 
especially given that there are equal numbers of male and female mice in each group 
(N=20 or 21).
4.2.8 OS47720 Rescues Working Memory and Spatial and Learning Memory 
Deficits in Presymptomatic Tg2576 Mice
All groups of mice were tested for their working memory after chronic OS47720 
treatment in a cross maze test. Total entries were recorded for basal activity and 
alternation rate was calculated and analyzed as the measure of memory. Working 
memory was greatly impaired in the Tg2576 group, as indicated by significantly lower 
alternation rate on the cross maze test, and this was almost completely rescued by 
OS47720 (Figure 4-8A and B).  
The Morris water maze test was utilized to measure spatial and learning memory. 
Experimental schedule is shown in Figure 4-8C. Distance was used as a dependent 
measure because of a slightly (but non-significant) faster swimming speed in the Tg-
Vehicle group, compared to the other three groups.  Mice in all groups readily found the 
cued platform (Figure 4-8D). On the hidden-platform training, there were significant 
effects of genotype and drug, and a significant Genotype x Drug interaction. Vehicle-
treated Tg mice were significantly impaired relative to their Non-Tg counterparts (Figure 
4-8D), consistent with previous reports in these mice (Westerman et al., 2002). OS47720 
treatment rescued the spatial learning impairment in the Tg group, demonstrated by
significantly shorter swim paths. OS47720 treatment did not improve spatial learning and
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Figure 4-7 Locomotor Activity and Anxiety Level after 3-month Treatment of 
OS47720.
(A-C) Locomotor activity in 12-month old Tg2576. Locomotor activity was measured by 
an open field test in all four groups. Numbers of beam breaks, distance travelled (inches), 
and time (s) spent in the center were measured. (D and E) Anxiety level was measured in 
the elevated-plus maze. Total arm entries, and percentage of time spent on closed, and 
open arms and in the central area, were also measured. N=20 or 21 each group. One-way 
ANOVA was performed. No significant differences were noted.
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Figure 4-8 In vivo Therapeutic Efficacy of OS47720 in Tg2576 Mice.
Tg2576 mice and their littermates were administrated vehicle control or OS47720 
treatment (100 mg/kg) via i.p. for a total of 3 months, starting from 9 months of age.  
Cross maze and Morris water maze (N=20-21) were conducted at 12 months of age. (A) 
Total entries in cross maze among four experimental groups. (B) Alteration rate (%) 
representing working memory on cross maze was calculated based on times of alterations 
and total entries. (C) Schematic diagram shows schedule of Morris water maze 
experiment. (D) Distance swam was used in Morris water maze test to evaluate spatial 
and learning memory. Histogram represents distance swam (cm) cued and hidden 
platform sessions. Distance was averaged every two days in hidden platform session. (E) 
Time spent in target (40 cm) and non-target zones during probe session were analyzed 
among groups. (F) Schematic diagram shows target zone surrounding previous location 
of platform and non-target zone along the pool. (G) Representative images of the heat 
map from each experimental group during the probe session. One-way ANOVA with 
Tukey’s post hoc test. *P < 0.05, ***P < 0.001. Data are represented as mean ± SEM.
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memory in the non-Tg mice and there was no genotypic difference in the OS47720-
treated mice (Figure 4-8D). A probe trial was conducted 24 h after the last hidden-
platform session to assess memory for the former platform location. Time spent in a 40-
cm zone centered on the former platform location was used as an index of spatial 
memory as it was a more precise measure in the target quadrant (Figure 4-8F). The 
vehicle-treated transgenic mice did not spend significantly more time in the target zone, 
when compared to the mean of the other three zones (Figure 4-8E). Similarly, these mice 
did not discriminate between the former platform location and equivalent positions in the 
other three quadrants. In contrast, mice in the other three groups showed a selective 
search for the targets. Heat maps show a more defined swim path in OS47720 -treated 
groups, indicating superior spatial reference memory (Figure 4-8G).
4.2.9 Protein Changes in Presymptomatic Tg2576 Mice after OS47720 Treatment
To test for underlying protein changes after chronic treatment. Tissue samples 
from the hippocampus were harvested from the mice from each group. Western blot 
analysis was conducted to examine several proteins of interest, including heat shock 
proteins such as HSF1, iHsp70, Hsp40, synaptic proteins such as PSD95, synapsin I, 
SNAP25, as well as BDNF.
Consistent with our in vitro data, the expression levels of heat shock proteins 
including HSF1, iHsp70 and Hsp40 were boosted by OS47720 treatment either in two 
NonTg2576 groups (NonTg-Veh and NonTg-OS47720), or in two Tg2576 groups (Tg-
Veh and Tg-OS47720) (Figure 4-9A). This indicates the ability of OS47720 to induce a 
heat shock-like response in the brain through systemic i.p. injection. Moreover, a 
reduction of heat shock proteins in Tg-Veh group of mice was also observed. In 
NonTg2576 groups, OS47720 did not significantly upregulate synaptic proteins except 
for synapsin I and had no effect on BDNF. However, select synaptic proteins, PSD95 and 
BDNF, were largely restored back to control levels (NonTg-Veh) in the hippocampi of 
Tg2576 mice after chronic OS47720 treatment (Figure 4-9A). Quantification analysis 
revealed significant changes occurred in the brain (Figure 4-9B)
4.2.10 OS47720 Rescues Working Memory and Spatial and Learning Memory 
Deficits in Symptomatic Tg2576 Mice
Successful chronic treatment of presymptomatic Tg2576 mice lead to testing 
repeated OS47720 injections (100 mg/kg i.p.; every 2 days for the first 2 month, and 
twice a week thereafter until 6 months) as a chronic treatment on symptomatic (middle-
stage) Tg2576 mice from 12 months to 18 months of age. Mice were divided into the 
following four groups: 1. NonTg2576 group (NonTg); 2. NonTg2576-Vehicle group 
(NonTg-Veh); 3. Tg2576-Vehicle group (Tg-Veh); 4. Tg2576-OS47720 group (NonTg-
OS47720). There were 10-13 mice in each group with about half males and half females. 
A NonTg2576 group without vehicle treatment was introduced to test if the vehicle itself
caused any systemic effect either on body weight or behavior. However, the NonTg-
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Figure 4-9 End Point Western Blot Analysis after 3-month Treatment of 
OS47720.
Hippocampal tissues were collected for protein analysis after behavior testes. (A) 
Representative images (4 mice from each group) of Western blot analysis after Morris 
water maze. HSF1, Heat shock proteins (iHsp70, and Hsp40), synaptic proteins (PSD95, 
synapsin I, and SNAP25) and BDNF were tested in four groups; (B) Statistical analysis 
of the Western blot data presented in (g). N=6. One-way ANOVA with Tukey’s post hoc 
test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are represented as mean ± SEM.
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OS47720 group was not included this time due to the limited quantity of OS47720 
compound. Besides, OS47720 had been proven to induce heat shock-like response and
several synaptic proteins in presymptomatic Tg2576 mice. Similar to previous results, the 
working memory deficit in the Tg-Veh group was significantly improved by OS47720 
treatment in Tg mice, with no difference in total entries among all groups (Figure 4-10A 
and B). The Morris water maze test revealed impaired long-term spatial learning and 
memory in the Tg-Veh group, which was significantly improved in the Tg-OS47720 
group to the point where memory was comparable to that of the non-Tg and non-Tg-Veh 
groups (Figure 4-10C). During probe trial sessions, the Tg-Veh group lacked preference 
in the target search, while the other three groups selectively searched for the target zone 
(Figure 4-10D). Vehicle treatment had no effect on cross maze or Morris water maze 
tests. Taken together, OS47720 exhibited its ability to reverse memory loss in both 
presymptomatic and symptomatic Tg2576 mice. 
4.2.11 End Point Study Revealed Protein Changes in Symptomatic Tg2576 Mice 
after OS47720 Treatment
Western blot analysis was also conducted to examine changes in select proteins in 
symptomatic Tg2576 mice after chronic OS47720 treatment. Tissue samples from 
hippocampus were also collected for biochemistry analysis. 
Vehicle treatment induced iHsp70 protein, though not significant, in NonTg2576 
mice. However the other two heat shock proteins HSF1 and Hsp40 remained unchanged. 
Vehicle itself did not change levels of select synaptic proteins (Figure 4-11A). In the 
Tg2576 groups, Heat shock proteins, PSD95 and BDNF were all reduced in the Tg-Veh 
group of mice. Chronic treatment of OS47720 reversed not only all heat shock proteins 
tested, but also synaptic protein PSD95 and BDNF (Figure 4-11A). Quantification 
analysis demonstrated the significant protection of OS47720 in Tg2576 mice (Figure 
4-11B). This result is consistent with the conclusion from previous results of 3 month 
treatment. In summary, OS47720 sufficiently exhibited its therapeutic potential in 
preventing memory loss in presymptomatic and symptomatic stages of Tg2576 mice, 
accompanied by the recovery of impaired heat shock-like response, synaptic proteins and 
BDNF. 
4.2.12 Body Weight Changes in Presymptomatic and Symptomatic Tg2576 Mice 
During OS47720 Treatment
Body weight was not significantly changed during the 3 month chronic treatment 
of OS47720 treatment in presymptomatic Tg2576 in either males or females (Figure
4-12A and B). There was a slight decrease in body weight (10-14% on males and 5-12% 
on females) over a 6-month treatment course in all vehicle and OS47720 treatment 
groups, suggesting mild toxicity or stress caused by the vehicle. However, OS47720
treatment itself did not cause obvious weight loss (Figure 4-12C and D). These data
confirm the low toxicity of the OS47720 compound.
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Figure 4-10 Effects on Symptomatic Tg2576 Mice after 6-month Treatment of 
OS47720.
Each group includes half males and females. (A) Total entries in the cross maze. (B) 
Alteration rate (%) representing working memory on the cross maze was calculated as the 
number of alterations divided by (total entries-3) x100. (C) Distance swam was used in 
the Morris water maze test to evaluate spatial and learning memory. Histogram represents 
distance swam (cm) in cued and hidden platform sessions. Distance was averaged every 
two days in the hidden platform sessions; (D) Time spent in the target (40 cm) and non-
target zones during probe session was analyzed among groups. N=10-13. One-way 
ANOVA was performed followed by Tukey’s Post hoc test. NonTg-Veh vs NonTg-
OS47720, Tg-Veh vs NonTg-Veh, Tg-Veh vs Tg-OS47720, *P < 0.05, **P < 0.01 and 
***P < 0.001. Data are represented as means ± SEM.
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Figure 4-11 End Point Western Blot Analysis after 6-month Treatment of 
OS47720.
(A) Western blot analysis on post-mortem hippocampal tissue followed by quantification. 
3 or 4 representative samples were shown. N=5-6. (B) Quantification analysis based on 
the Western blot images. One-way ANOVA was performed followed by Tukey’s Post 
hoc test, NonTg-Veh vs NonTg-OS47720, Tg-Veh vs NonTg-Veh, Tg-Veh vs Tg-
OS47720, *P < 0.05, **P < 0.01 and ***P < 0.001. Data are represented as means ± 
SEM.
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Figure 4-12 Body Weights from Two Cohorts of Tg2576 Mice with Chronic 
Treatment of OS47720.
(A, B) Weight data during 3 months of treatment (n = 20 or 21). (C, D) Weight data 
during 6 months of treatment (n = 11-13). Males and females are presented separately.
Weight was measured at indicated days or weeks shown on X-axis.
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4.3 Summary
In this chapter, a novel CNS-permeable Hsp90 inhibitor OS47720 was studied for 
its in vitro and in vivo efficacy. OS47720 produced an effect comparable to that of 17-
AAG, as shown in the previous chapter, of inducing HSF1 nuclear translocation, heat 
shock-like responses and synaptic proteins. Similarly, structural changes in dendritic 
spines were also observed by IF staining. 
In histologic analysis, OS47720 firstly exhibited a superb safety profile without 
any visible pathological changes in liver and kidney after in vivo use in mouse. LC-MS 
showed rapid brain accumulation of OS47720 within 1h and confirmed its CNS-
permeability after a single i.p. injection of OS47720. Although the compound gradually 
cleared from the brain after 24 h, the pharmacodynamic effect of inducing iHsp70 and 
PSD95 lasted for at least 3 days, which was further confirmed in iHsp70-mPlum reporter 
mice. Most interestingly, hippocampal CA1 region exhibited the greatest response, 
compared with other regions within the hippocampus and cerebral cortex, which 
suggested a possible memory enhancement since the hippocampus is closely related to 
memory. 
With behavior approaches, OS47720 firstly displayed protection on memory 
????????????????????????????????????????????????????????????????????????????????????????
OS47720 for 3 months and 6 months of Tg2576 mice at early and middle symptomatic 
stages revealed completely rescued both a short-term memory (working memory) deficit 
in the cross maze and a long-term memory (spatial and learning memory) deficit in the 
Morris water maze. Post-mortem biochemical study revealed underlying molecular 
changes. All heat shock proteins, synaptic proteins, as well as BDNF were restored to the 
level comparable to non-Tg mice after OS47720 treatment. Additionally, OS47720 did 
not affect locomotor activity or anxiety-related behavior during chronic treatment. No 
significant body weight reduction was observed in all groups tested, indicating a feasible 
treatment range. 
In conclusion, the CNS-permeable OS47720 compound provided convincing in 
vivo efficacy results without any systemic toxicity during various behavior tests. These 
findings verify and support the potential of a therapeutic strategy of targeting Hsp90 
inhibition in AD.
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CHAPTER 5.   MECHANISTIC STUDY
5.1 Introduction
The initial finding of application of Hsp90 inhibitors on cancer treatment relied on 
degradation of Hsp90 client proteins. Similar to GA, radicicol and its derivatives, 
OS47720 binds to the ATPase binding site located at the N-terminus of Hsp90 protein 
complex, leading to dissociation of Hsp90 and its client proteins. Released client proteins 
can be degraded by ubiquitin–proteasome system (UPS). Since many client proteins are 
cancer-related, these compounds were actively tested for their antitumor effect.
Many neurodegenerative diseases are associated with misfolded proteins and 
protein aggregates, which are the targets of some of the traditional drug development. 
Clearance of these disease causing misfolded protein aggregates is believed to be 
beneficial during neurodegeneration. Lots of evidence showed that Hsp90 inhibition was 
able to reduce the misfolded protein load. Luo et al. (2007) showed the reduction of 
phosphorylated tau in JNPL3 tau Tg mice by acute (single injection; 1 d) treatment of the 
Hsp90 inhibitor PU-DZ8. In the same year, subchronic treatment (7 d) of the Hsp90 
inhibitor EC102 in Htau mice reduced tau aggregates (Dickey et al., 2007). More recently, 
Labbadia et al. (2011) found that orally administrated Hsp90 inhibitor NVP-Hsp990 
(Novartis compound) transiently reduced Huntingtin protein load. Although until there 
had been no in vivo work done to investigate of the effect of the Hsp90 inhibitor ??????
clearance, all previous work of Hsp90 inhibitor on other disease proteins implies a 
potential function of OS47720 on Tg2576. In the ??????????????????????????????????????
among experimental groups.
It is also known that heat shock proteins are protective to cells under internal or 
external stress (Brown, 2007). Direct overexpression of Hsp70 reduced polyglutamine 
aggregation in vitro transfected cells. In Drosophila, direct expression of Hsp70 
suppresses polyglutamine-induced neurodegeneration in vivo (Warrick et al., 1999). Later 
study in mammalian cell models of HD, bacterial chaperone and yeast Hsp40 were found 
to reduce polyglutamine aggregation and prevent cell death (Carmichael et al., 2000). 
Upregulation of heat shock proteins by the pharmacological agent BRX-220 increased 
the survival of injured motor neurons and promoted morphological and functional 
improvement in the sensory system after peripheral nerve injury (Kalmar et al., 2002; 
Kalmar et al., 2003). Induction of heat shock proteins also delayed disease progression in 
ALS mice expressing a SOD1 mutant (Kieran et al., 2004). There were also findings 
suggesting Hsp90 inhibitors work as inducers of heat shock proteins to treat 
neurodegeneration. In a cell culture model of HD, treatment of GA induced expression of 
heat shock proteins (Hsp90, Hsp70 and Hsp40), and inhibited HD exon I protein 
aggregation in a dose-dependent manner. The effect was replicated by overexpression of 
Hsp70 and Hsp40 in a separate cell culture model of HD (Sitter et al., 2001).
HSF1 is known as a master transcriptional heat shock response regulator to induce 
heat shock proteins. OS47720 activated HSF1 nuclear translocation and transcriptional 
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activity, which led to further investigation of HSF1-mediated regulation underlying 
OS47720’s therapeutic effect in Tg2576 mice. Besides, inspired by 17-AAG study, novel 
regulation of HSF1 in synaptic proteins and BDNF was also examined in current 
experimental settings. 
5.2 Results
5.2.1 OS47720 Did Not A?????????Level and Neuroinflammation
As shown by the in vivo efficacy study described above, OS47720 rescued 
memory loss in Tg2576 mice. The question remained as to how OS47720 improved 
memory. As an APP overexpressing mouse model of AD, Tg2576 mice had been well 
characterized by memory impairments closely correlat???????????????????????????????????
the cortex and hippocampus. 
????????????????????????????????????????????????????????????????????????????
?????????? ??????? ??????????????????????????????????????????????????????????????????
plaque formation in the Tg-Veh group of mice, while treatment of 0S47720 did not 
??????????????????????????????????Figure 5-1A). 
???????????????????????????????????????????????????????????????????????????
of mice from Tg-Veh group and Tg-OS47720 group were collected and processed 
acco???????????????????????????????????????????-??????????????????-????????????????-40
??????????????????-40 were tested separately. There was no significant change in either 
??????????????????????????-?????????????????????????????????-40 after 6 month chronic
OS47720 treatment (Figure 5-1B). Both immunohistological staining and ELISA 
?????????????????????????????????????????????????????????????????????
Neuroinflammation accompanies the pathological process of AD and plays an 
important role. However it is still not clear whether it is a causal or responsive event to 
disease pathology (Heneka et al., 2015). Typical neuroinflammation in AD involves an 
astrocytic response and microglial activation, which can be visualized by 
immunofluorescence staining of their respective protein markers glial fibrillary acidic 
protein (GFAP)  and ionized calcium-binding adapter molecule 1 (Iba1). Representative 
images shown in Figure 5-1C revealed treatment of OS47720 did not change general 
neuroinflammation levels in the hippocampus and cerebral cortex.
5.2.2 KRIBB11 Abolished Heat Shock-like Response and Contextual Conditioned 
Freezing Memory
It was hypothesized that OS47720 improved memory through activation of HSF1. 
To test this hypothesis, HSF1 manipulation is desired. First, an HSF1-specific 
pharmacological inhibitor KRIBB11 was used to downregulate HSF1 protein expression 
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Figure 5-1 OS47720 Treatment Has No E????????????????Plaque Load in 18 
Month-old Tg2576 Mice.
(A) Representative fluorescence images from immuno-?????????????????????????????????
in Tg2576 mouse brain (coronal). Scale bar is 200 μm. (B) ELISA of soluble and 
?????????????-??????????-42 using hippocampal tissue from Tg-Veh and Tg-OS47720 
groups. (C) Representative fluorescence images from immuno-staining of GFAP (green; 
upper row) and Iba1 (red; bottom row) in Tg2576 mouse brain (coronal). Scale bar is 200 
μm.
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(Yoon et al., 2011). KRIBB11 was microinjected into mice at the same triple time points 
as indicated in Figure 3-4A ??????????????????????????????????????????????????????????
microinjected for side by side comparisons with KRIBB11.
??????????????????????????????????????????????????????????????????????????????
fear acquisition (Figure 5-2A??????????????????????????????????????????????????
consistently reduced the percentage of freezing time at the 48 h and 72 h time points. 
Triple injections of KRIBB11 impaired contextual conditioned freezing memory even 
?????????????????????????????????????????????????????????????????????????????????????????
by even lower percentage of freezing times recorded during contextual fear retention 
(Figure 5-2B). This was accompanied by marked reductions of HSF1, HSPs, and various 
synaptic proteins (Figure 5-2C and D). This finding suggests the requirement of HSF1 
for the contextual conditioned freezing memory.
In order to further confirm the pharmacological effect of KRIBB11 in the brain, 
KRIBB11 was microinjected into the lateral ventricle through i.c.v. administration. 
Hippocampi tissues were collected and processed for Western blot analysis. Figure 5-2C 
and D showed that not only were heat shock proteins reduced, but also select synaptic 
proteins, including PSD95 and synapsin I, were greatly downregulated by KRIBB11.
5.2.3 Upregulation and Downregulation of HSF1 by Viruses
In order to address the role of HSF1 underlying OS47720’s effect, adeno-
associated viruses (AAV) were utilized. HSF1 was upregulated by using AAVH-BH
which overexpressed a constitutively active HSF1 (AAVH-BH) (Jung et al., 2008), while 
HSF1 was downregulated by using AAVshRNAhsf1.
Both viruses were introduced into cultured primary neurons from hippocampus, 
with or without a co-treatment of OS47720 (100nM). Consistent with previous results, 
OS47720 treatment alone induced heat shock proteins, PSD95 and BDNF. AAVH-BH 
greatly increased protein levels of HSF1, which transcriptionally upregulated the 
expression of its downstream heat shock proteins expression (iHsp70, Hsp40 and Hsp27). 
Not surprisingly, PSD95 and BDNF were also upregulated. However co-treatment of 
OS47720 did not further increase heat shock proteins, PSD95 and BDNF. 
AAVshRNAhsf1 significantly reduced the expression of HSF1, which also 
transcriptionally reduced downstream heat shock protein expression. AAVshRNAhsf1 
partially abolished OS47720’s effect on increasing heat shock proteins, PSD95 and 
BDNF (Figure 5-3A). Quantification analysis is shown in Figure 5-3B. Therefore, 
upregulation or downregulation of HSF1 by AAVs resulted in opposite consequences of 
heat shock-like response (e.g., iHsp70), synaptic proteins (PSD95) and BDNF.
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Figure 5-2 KRIBB11 Abolishes Contextual Fear Memory.
(A) Freezing time (%) during fear acquisition (training) in the contextual fear 
conditioning test. Ctrl, control. (B) Recorded contextual fear retention (context retrieval) 
24, 48 and 72 h after training. One-way ANOVA was performed followed by Tukey’s 
?????????????????????????????????????????????????????????????????????????-13. (C) Western 
blot analysis on the hippocampi of mice treated with the pharmacological inhibitor 
KRIBB11, 4 h after i.c.v. injection. Protein levels of HSF1, iHsp70, Hsp40, Hsp27, 
synapsin I and PSD95 were determined. n = 3. (D) Histogram shows the statistical 
analysis (Two-sample student t-test, *P < 0.05 and **P < 0.01). Data are represented as 
means ± SEM.
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Figure 5-3 Upregulation and Downregulation of HSF1 by AAVH-BH and 
AAVshRNAhsf1 in Cultured Primary Neurons.
(A) AAVH-BH and AAVshRNAhsf1 were introduced to cultured primary hippocampal 
neurons at 7-10 DIV. OS47720 (100 nM) was added 5-7 days after viral infection and 
was incubated for 24 hours. Western blot analysis was performed afterwards. (B) 
Statistical analysis of quantification using one-way ANOVA on 3 independent 
experiments, followed by Tukey’s post hoc test, all groups were compared with control 
except the AAVshRNAhsf1+OS47720  group, which was compared with OS47720. n.s., 
non-significant. n = 3. Means ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001.
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5.2.4 Downregulation of HSF1 by AAVshRNAhsf1 Abolished the Effect of 
OS47720
Since both AAVs had been tested for their effect on regulation of HSF1 in in vitro
cultured primary neurons, they were further introduced to in vivo study, where they were 
microinjected into mouse brain. It was hypothesized that OS47720’s effect was mediated 
by HSF1. AAVshRNAhsf1 was first used to test if OS47720 could work independently 
of HSF1. AAVshRNAhsf1 also contained a construct expressing EGFP that can be 
visualized under the fluorescence microscope. 
Small volumes of AAVshRNAhsf1 (1.5μl) were microinjected bilaterally into 
brain hippocampi over 10 minutes using stereotaxic technique. Three weeks after 
injection, EGFP was observed specifically in the hippocampal region (Figure 5-4A). 
During contextual fear conditioning, the AAV-mediated downregulation of HSF1, 
diminished contextual conditioned freezing memory at both 48 and 72 h after training 
which could not be rescued by OS47720 (Figure 5-4B and C). In contrast, OS47720-
treated mice had slightly higher basal contextual conditioned freezing memory at these 
time points. An end-point study of the altered proteins revealed abolished Hsp40, PSD95, 
and mature BDNF by AAVshRNAhsf1 administration; changes that were not restored by 
OS47720  treatment (Figure 5-4D and E).
5.2.5 HSF1 Heterozygous Mice Exhibited Impaired Memory
HSF1 was further examined for its role in memory regulation by using HSF1 
heterozygous mice. A breeding pair of heterozygous HSF1 mice was purchased from the 
Jackson laboratory. About 60 offspring were born from 13 litters. However the 
genotyping revealed that no knockout mice survived, mainly because of the critical role 
of HSF1 in development. Therefore adult (4-6 months old) HSF1 heterozygous mice (+/-)
were used and compared in memory tasks with their WT littermate controls. Working 
memory was evaluated by cross maze. Recognition memory was evaluated by a novel 
object recognition task. Locomotor activity was measured by the open field test. Anxiety-
related behavior was measured by elevated plus maze. 
During cross maze test, heterozygous mice (N=14) showed comparable total 
entries with WT control mice (N=12) (Figure 5-5A), but a significantly lower alternation 
rate, indicating impaired working memory (Figure 5-5B). The open field test revealed 
less locomotor activity in heterozygous mice as evidenced by the shorter distance 
travelled (Figure 5-5C). During the novel object recognition task, both groups of mice 
showed similar exploration times (Figure 5-5D). WT mice showed slightly higher 
exploration time of the novel object over an old object, while heterozygous mice did not 
differ between two objects (Figure 5-5E). WT mice showed a significantly higher 
discrimination index than heterozygous mice which indicates a better recognition 
memory (Figure 5-5F). Anxiety was not affected by lowered HSF1 in heterozygous mice 
as there was no difference among all parameters examined in elevated plus maze (Figure 
5-5G and H).  Western blot analysis confirmed HSF1 protein reduction in
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Figure 5-4 AAVshRNAhsf1 Abolishes the Effect of OS47720 in Contextual Fear 
Conditioning.
(A) EGFP expression in mouse brain 14 days after AAVshRNAhsf1 was stereotaxically 
microinjected into hippocampus. Scale bar is 100 μm. (B and C) Freezing time (%) 
during fear acquisition and contextual fear retention in the contextual fear conditioning 
test. N=10-12. One-way ANOVA with Tukey’s post hoc test, ctrl vs AAVshRNAhsf1.
*P < 0.05. (D) Representative images of Western blot analysis after contextual fear 
conditioning. (E) Statistical analysis of the Western blot data. n = 6. One-way ANOVA 
with Tukey’s post hoc test, *P < 0.05, *P < 0.01 and ***P < 0.001. Data are represented 
as means ± SEM.
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Figure 5-5 Behavioral Tests on Young Adult HSF1+/- and Littermate Control 
Mice.
(A, B) Total entries and alternation rate (%) in cross maze test. (C) Total distance (inch) 
traveled from open field test indicating locomotor activity. (D-F) Total object exploration 
time, exploration time and discrimination index in the novel object recognition task. (G 
and H) Anxiety level was examined by arm (closed, open and total) entries and 
percentage of time on arms and center in the elevated plus maze. N=12 or 14, Means ± 
SEM. Two-sample Student’s t-test, *P < 0.05 and **P < 0.01. (I) Images from Western 
blot analysis shown total HSF1 protein reduction in HSF1 +/- mice, compared with 
wildtype littermates’ control.
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heterozygotes (Figure 5-5I). These results suggested HSF1 is required for memory 
process.
5.2.6 Overexpression of HSF1 by AAVH-BH Slightly Improved Contextual 
Conditioned Freezing Memory
Since it had been addressed that HSF1 is required for OS47720’s effect by 
reducing HSF1 in previous experiments, the next question was whether overexpression of 
HSF1 has a comparable effect to OS47720. Mice were divided into the following four 
groups: 1. AAVYFP; 2. AAVH-?????????????????????????-???????????-BH, 
????????????????????????????????????? ????????????????????????????????????
stereotaxic technique. Each after 3 weeks, contextual fear conditioning was conducted.  
Figure 5-6A showed HSF1 was greatly upregulated, together with increases of iHsp70 
and Hsp27. Interestingly, PSD95 and BDNF were also upregulated (Figure 5-6A). 
During contextual fear conditioning training, there was no difference in freezing time 
among groups (Figure 5-6B??????????????????????????????????????????????????????
contextual conditioned freezing memory. Overexpression of AAVH-BH slightly 
????????????????????????????????????????? ????????????????????????????????????????????
though no significance was reached (Figure 5-6C). These results suggested that HSF1 
contributed to the memory process. 
5.2.7 HSF1 Is Required for the Initial Stage of Memory Consolidation and 
Retrieval
To determine whether the requirement of HSF1 is more crucial in the initial stage 
of memory acquisition and consolidation or for all stages (including retrieval and 
extinction), KRIBB11 was administered via implanted cannula at 1 h before and 1, 3, 6, 8, 
and 24 h after training. The most significant abrogating effect was observed at 1 h post-
training, and to a lesser degree at 3 and 6 h post-training. No effect was observed when 
injected at 8 or 24 h post-training (Figure 5-7). These results indicate that HSF1 is 
required for the initial stage of memory consolidation or retrieval.
5.2.8 HSF1 Overexpression Induced BDNF Expression
Because OS47720 was able to induce protein expression of BDNF, it would be 
interesting to see if BDNF could upregulated directly by overexpression of HSF1. 
Overexpression of a construct to constitutively activate HSF1 (Jung et al., 2008) in 
cultured hippocampal neurons markedly induced BDNF expression, as both pro and 
mature forms of BDNF protein levels were significantly increased (Figure 5-8A, B and
C), so was BDNF mRNA level (Figure 5-8D). 
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Figure 5-6 Overexpression of H-BH Did Not Exhibit Comparable 
Neuroprotection to OS47720 in Mice.
(A) Western Blot of hippocampus collected from mice receiving AAV H-BH for 3 weeks 
at CA1. (B and C) Fear acquisition and freezing time (%) of contextual fear retention. n = 
10=13. One-way ANOVA with Tukey’s post hoc test was performed. No significance 
was found. Data are represented as means ± SEM.
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Figure 5-7 Time Course Study of KRIBB11 Treatment in Contextual 
Conditioned Freezing Memory Test.
KRIBB11 at the dose of 2ul/2mM was injected through implanted cannulas to lateral 
ventricle (i.c.v.) for 10 min. (A) Freezing time (%) during fear acquisition (training). (B-
D) Freezing time (%) of contextual fear retention, 24, 48 and 72 h after training. n = 18 
(ctrl) or 6 (KRIBB11-treated groups). One-way ANOVA was performed followed by 
Tukey’s post hoc test. *P < 0.05. Data are represented as means ± SEM.
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Figure 5-8 BDNF Regulation by HSF1.
Primary cultured hippocampal neurons were infected with AAVH-BH and AAV1-YFP 
control for 7 days. (A) Western blot analysis was performed to detect both precursor 
BDNF (pro-BDNF) and mature BDNF on 3 independent experiments. Un: untreated. 
Histograms show statistical analysis on changes of pro-BDNF (C) and mature BDNF (B). 
(D) The mRNA levels of HSF1 were determined by qRT-PCR after viral infection N=3. 
One-way ANOVA with Tukey’s post hoc test, ***P < 0.001. Data are represented as 
means ± SEM.
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5.2.9 OS47720’s Effect Bypasses cAMP/PKA and PI3K/AKT Pathways but
Requires CaMKII
To determine whether OS47720 induced BDNF upregulation via the classic 
cAMP-PKA-CREB pathway, cAMP levels were measured in cultured hippocampal
neurons. OS47720 did not alter intracellular cAMP production even when a priming 
concentration of forskolin was given (Figure 5-9A). The lack of a role of the cAMP-
PKA-CREB, MAPK, and PI3K pathways in the formation of dendritic spines was 
confirmed by pharmacological inhibitors (i.e., RpcAMP and H89, U0126 and LY294002; 
Figure 5-9B).,These results are consistent with our previous reports showing reduced 
AKT levels upon Hsp90 inhibition in neurons (Chen et al., 2014). A CaMKII inhibitor 
did reduce the effect of OS47720 on dendritic spines. Statistical analysis revealed 
significant loss of dendritic spines using KN93, a selective CaMKII inhibitor, with or 
without co-treatment of OS47720, while no effect was observed by using its inactive 
derivative, KN92 (Figure 5-9C). 
5.3 Summary
This chapter investigated molecular mechanism underlying the therapeutic effect 
from OS47720 chronic treatment. 
Most Hsp90 inhibitors display neuroprotection in neurodegenerative diseases by 
degrading misfolded proteins or aggregates. In contrast, OS47720 did not significantly 
?????????????????????????????????????????????????????????????????????????????????????
Tg2576 mice. Downregulation of HSF1 by both a pharmacological inhibitor KRIBB11 
and by AAVshRNAhsf1, abolished OS47720’s effects in the memory tests. Meanwhile, 
HSF1 overexpression by AAVH-BH partially increased contextual conditioned freezing 
memory. Moreover, HSF1 heterozygous mice showed impaired memory suggesting the 
requirement of HSF1 in memory regulation. Time course study of KRIBB11 treatment 
revealed that HSF1 is required for the initial stage of memory consolidation or retrieval. 
Further biochemical study showed BDNF was directly regulated by HSF1 at the 
transcription level. Taken together these results indicate the existence of an HSF1-
mediated mechanism underlying OS47720’s effect, which required CaMKII but bypassed 
the several important signaling pathways, including the cAMP/PKA and PI3K/AKT 
pathways.
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Figure 5-9 Hsp90 Inhibition Bypasses Several Major Signaling Pathways.
(A) Primary hippocampal neurons (21 DIV) were used for studying the impact of 
OS47720 treatment on cAMP levels. Foskolin (Fsk) at 10 μM and 0.1μM was used as 
positive control. cAMP levels were determined 15 min after Fsk and OS47720 treatment, 
using the HitHunter cAMP Assay for Small Molecules kit (DiscoveRx, Inc.) following 
the manufacturer’s instructions. Data are presented as the result of 3 independent 
experiments (triplicated).  (B) Confocal imaging of dendritic spines at 24 h after 
treatment of various pathway inhibitors in 14 DIV cultured primary hippocampal neurons. 
Inhibitors includes U0126, a selective inhibitor of the MAP kinase kinases/ MEK1 and 
MEK2; H89, PKA Kinase Inhibitor; Rp-cAMPS, a potent and specific competitive 
inhibitor of the activation of PKA by cAMP; LY294002, phosphatidylinositol 3-kinase 
(PI3K) inhibitor; KN93, a selective inhibitor of CaMKII; KN92, structural analog & 
inactive form of KN-93. All inhibitor compounds were used at 10 μM. Scale bar is 5 μm.
(C) Spine quantification based on 10 fields per slide. n = 3. One-way ANOVA was 
performed followed by Tukey’s post hoc test. *P < 0.05.
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CHAPTER 6.   DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Discussion
6.1.1 Investigation of Hsp90 Inhibitors in Neurodegenerative Diseases
Targeting Hsp90 with chemical inhibitors has long been an area of investigation 
in treating various types of cancer (Neckers, 2002; Whitesell and Lindquist, 2005). Many 
of these inhibitors are currently undergoing clinical trials, as in the case of SNX-5422 in 
(phase I), AUY-922 in (phase I/II), PU-H71 (phase I), etc. Limited clinical success has 
been achieved with several agents in certain types of tumors. Currently there is a lack of 
clinicaly approved Hsp90-targeting agents for cancer therapy. 
Hsp90 inhibitors have also long been investigated for treatment of 
neurodegenerative diseases. While much of the experimental data has been obtained from 
in vitro studies, very limited success was achieved in vivo. Ansar et al. (2007) 
investigated a small molecule novobiocin analogue called A4, a C-terminus inhibitor of 
Hsp90, which induces Hsp90 protein overexpression, and also upregulates Hsp70 
?????????????????????????????????????????????????????????????????????y in cultured 
primary cortical neurons (Ansar et al., 2007). That group later confirmed that both A4 
and another novobiocin analogue, KU32, exhibited neuroprotective properties against 
??-induced cell death as measured, by lactate dehydrogenase (LDH) activity assay in 
differentiated SH-SY5Y neuronal cells (Lu et al., 2009). Tau-pathology has also been 
tested after Hsp90 inhibition from two other groups. In 2007, Dickey et al. targeted 
Hsp90 inhibition by the inhibitor EC102, showing preferential degradation of 
phosphorylated tau protein in the following models: Chinese hamster ovary (CHO) cells 
and human embryonic kidney (HEK293) cells overexpressing P301L mutant tau, in Hela 
cells overexpressing V5-tagged tau (V5-tau), and in AD transgenic mice (Htau mice) 
expressing human tau protein. All of these aforementioned models produced the 6 splice 
variants of the human tau protein, representing progressive pathogenesis of tauopathies 
(Dickey et al., 2007). In the meantime, it was Luo et al. (2007) who first demonstrated a 
reduced level of phosphorylated tau in cultured embryonic primary cortical neurons and 
COS-7 cells transfected with human tau cDNAs with P301L mutation, by using their 
laboratory synthesized Hsp90 inhibitor PU24FCl. Besides the in vitro findings, they also 
found a reduction of aggregated and hyperphosphorylated tau in an AD mouse model 
representing tauopathy (JNPL3 mice) by using a blood-brain barrier (BBB) permeable 
Hsp90 inhibitor PU-DZ8 (Luo et al., 2007). Other diseases with mutated proteins have 
also been investigated. Riedel and his colleagues reported that 17-AAG significantly 
??????????????????????????-synuclein aggregates in an oligodendroglia cell line (OLN-93
????????????????????????????????? ????????-synuclein (Riedel et al., 2010). It was
around the same time that Putcha and her colleagues used an Hsp90 inhibitor (SNX-2112) 
????????????-synuclein induced toxicity (Pucha et al., 2010). In vivo pharmacokinetic and 
pharmacodynamic assessments of this SNX compound were also tested by this group; 
however no further in vivo efficacy was reported thereafter (Putcha et al., 2010). 
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Mutations in leucine-rich repeat kinase-2 (LRRK2) are well recognized as common 
causes of late-onset PD. 17-AAG had been discovered to be capable of reducing LRRK2 
in SH-SY5Y cells (Ko et al., 2009). Using GA, 17-AAG, and radicicol in a primary 
culture model of familial amyotrophic lateral sclerosis (FALS), researchers found 
reduced aggregation of SOD1G93A, a distinguishing pathological and molecular feature 
of FALS (Batulan et al., 2006). Jinwal’s group demonstrated a clearance cascade for the 
TDP-43 protein through an internal autophagy system after Hsp90 inhibition by 17-AAG
in HeLa cells which had V5-tagged tau stably transfected (Jinwal et al., 2012). For 
studies in HD and other polyQ diseases, Sittler and his colleagues discovered that in an in 
vitro cell culture model, COS-1 cells overexpressing huntingtin exon 1 protein with 72 
glutamines [HD72Q], GA exhibited inhibition of protein aggregation of huntingtin 
(Sittler et al., 2001). Gregory’s group demonstrated that 17-AAG treatment reduces 
aggregation of ALS related protein TDP-43 in Drosophila (Gregory et al., 2012). 
Labbadia with his colleagues discovered a transient reduced Htt load in a Huntington’s 
disease mouse model, R6/2 mice, after administration of NVP-Hsp990, which is a 
Novartis compound of Hsp90 inhibition potency (Labbadia et al., 2011). It has been 
reported that GA reduced aggregation and promoted degradation of the abnormally 
glutamine-expanded androgen receptor (AR) in mouse embryonic fibroblasts (MEFs) 
(Thomas et al., 2006). Furthermore, Waza et al. (2005) found that 17-AAG was an 
effective treatment for spinobulbar muscular atrophy (SBMA), importantly being able to 
avoid issues dealing with CNS permeability (Waza et al., 2005). 
In addition to systemic toxicity, BBB penetrability has been a large obstacle in the 
development of drugs for CNS-related applications. Molecular size and lipophilicity are 
chief among physicochemical properties as the primary factors determining BBB 
penetrability. There is so far evidence of two CNS-permeable Hsp90 inhibitors that have 
successfully reduced tau aggregation with feasible toxicity profiles (Table 6-1). Luo et al. 
(2007) tested a single i.p. injection of PU-DZ8 compound on P301L tau transgenic 
(JNPL3) mice and found reduced tau aggregation after 24 h of treatment (Luo W et al., 
2007).  Dickey et al. (2007) observed reduced tau aggregation after 7 days of treatment of 
another Hsp90 inhibitor EC102 (Dickey et al., 2007). Both of these instances presented 
controversy in that they were either treated too acutely (single i.p. injection) or too briefly 
(only 7 days). Surprisingly, the Novartis compound NVP-Hsp990 (and NVP-AUY922 
from the same series) was ineffective against Huntington’s Htt R6/2, despite its efficacy 
in vitro (Labbadia et al., 2011). Interestingly, an earlier member of the same OS series of 
Hsp90 inhibitors (OS47701) also did not demonstrate efficacy in the ALS SODG93A4 
model due to minimum iHsp70 induced in the spinal cord (Cha et al. 2014).  The modest 
neuronal stress response after Hsp90 inhibition, as assessed by the induction of iHsp70, 
indicates infeasibility of using Hsp90 inhibitors in treating aggressive proteinopathies 
such as HD and ALS. The current study presents data demonstrating successful chronic 
(two cohorts of mice at 3 months and 6 months respectively) treatment of early-
symptomatic and middle-symptomatic staged Tg2576 mice with a CNS-permeable and 
non-toxic Hsp90 inhibiting compound. Based on our data, we conclude that Hsp90 
inhibitors have unique therapeutic value for AD because of their unique protective 
mechanism on synapses in preserving both synaptic structures and functions. The 
potential therapeutic implications of these findings are boundless, and are only further 
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Table 6-1 Summary of the In vivo Data Using Hsp90 Inhibitors in Neurodegeneration in Mouse Models.
Compound/ Source
Client protein/ 
Neurodegenerative 
disease
Administrative 
regimen
HSPs 
induction 
(e.g., 
iHsp70)
In vivo effect
Improved  
disease 
syndrome
References
PU-DZ8/  Sloan-
Kettering
Tau/AD 
(TauP301L/JNPL3)
i.p. injection; 75 mg/kg; 
single injection; 
duration: 1 day
n.d.
Reduce tau-
P/aggregation
n.d.
Luo et al. PNAS.
(2007)
EC102/ Conforma 
Therapeutics.
Tau/AD (humanized 
Htau )
i.p. injection; 200 mg/kg 
daily for 7 days
good
Reduce tau-
P/aggregation
n.d.
Dickey et al. J. 
Clin. Invest. (2007)
NVP-Hsp990/ Novartis Htt/HD (R6/2)
oral gavage; 12 mg/kg 
daily for 9 weeks
disrupted
Transiently 
reduce Htt load
No
Labbadia et al. J. 
Clin. Invest. (2011)
OS47720 (NXD30020)/ 
OncoSynergy
A??AD (Tg2576)
i.p. injection; 100 
mg/kg; two or three 
times per week for  3-6
months
modest
Rescue 
memory
(Behavior)
Yes Herein
Notes: Detailed Summary of the in vivo data from the CNS-permeable Hsp90 inhibitors in various mouse models of 
neurodegenerative diseases. n.d., not determined.
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encouraged by the favorable pharmacokinetics and pharmacodynamics of this compound 
(OS47720) (Table 4-1). 
6.1.2 Heat Shock Response in Neuronal Cells
In the past decade, the stress response to heat or Hsp90 inhibitors have generally 
been considered to be blunted in neurons. The inability to induce a heat shock response 
has been documented in mouse and rat primary culture neurons. In fact, as early as 1996,
Marcuccilli et al. found that primary cultured rat hippocampal neurons were unable to 
produce a heat shock response when subjected to hypothermia. However, a robust heat 
shock response was found in secondary cultured rat glial cells (Marcuccilli et al., 1996). 
In 2003, Batulan et al. (2003) discovered that cultured motor neurons failed to induce 
Hsp70 after excitotoxic glutamate, so did spinal cords from an ALS transgenic mouse 
model (SOD1G93A) and sporadic or familial ALS patients. When a constitutively active 
form of HSF1 was overexpressed, enhanced induction of Hsp70 was observed (Batulan et 
al., 2003). These results demonstrated that a failure to activate HSF1 led to a blunted 
response or created a high threshold for the neuronal heat shock response. It has thus 
been well accepted that an impaired heat shock response exists in neurons. 
While much of the data was generated through neuroblastoma or rodent primary 
neuronal culture models, admittedly there has been a lack of in vivo data. However, 
recently Carnemolla et al. (2015) performed an extensive and in-depth analysis of the 
heat shock response in the mouse brain and found that the brain was capable of 
maintaining a fairly strong heat shock response throughout its lifespan. This was either an 
indication that the heat shock response was not compromised in neuronal cells, or rather 
that non-neuronal cells were taking over the charge. The group further separated neurons 
and non-neuronal cells from mouse brains and performed extensive and in-depth analysis 
of heat shock response after Hsp90 inhibition by NVP-Hsp990. By using a neuronal 
purifying technique, they induced a heat shock response in striatal projection neurons. 
Their findings of an existing competent heat shock response in neurons ultimately 
supports our idea of developing therapeutics to neurodegenerative diseases targeting the 
heat shock pathways in neurodegenerative diseases.
Similarly, the ex vivo data (Figure 4-5) on the iHsp70 reporter mice after either 
single or continual OS47720 treatment also indicated a relatively weakened, but not 
blunted, neuronal HSF1/iHsp70 response in the brain relative to the liver and muscle. The 
hippocampal CA1 region demonstrated the greatest HSF1/iHsp70 response in the brain, 
while spinal cord motor neurons demonstrated almost undetectable responses (Figure 
4-4). This finding is consistent with previous reports that motor neurons have a 
comparatively high threshold for activation of genes for heat shock proteins, which may 
explain why this specific neuronal type is the most vulnerable and undergoes the most 
rapid degeneration (Cha et al., 2014). There are several possibilities for the weak heat 
shock response in most neurons, which may not be mutually exclusive: 1) the presence of 
intrinsic repressor(s) at the HSE sites. HSF-4a and HSF-4b were identified to be 
repressors of HSF1-mediated transcription by binding with HSEs (Zhang et al., 2001). 
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HSF-4a repressed the formation of HSF1 nuclear granules. 2) HSF1 itself is differently 
regulated in neurons. HSF1 is differently activated in development cells and in stressed 
cells. A unique trimerization mechanism underlies the effect of HSF1 protecting neurons 
from stress. It does not require the involvement of the expression of heat shock proteins 
such as Hsp70 or Hsp90 (Verma P et al., 2014). 3) The existence of an intrinsically inert 
neuronal iHsp70 promoter, which may interfere with the binding activity of HSF1. It was 
confirmed by Fernandez-Funez P et al. in a Drosophila model (Fernandez-Funez et al., 
2014). These possibilities require further investigation. 
In the current study, we did not detect any observable effects of reducing amyloid 
?????????????????? ????????????????? ??????????????????????????????????????????????
reports of anti-???????????????????y other Hsp90 inhibitors (Lu et al., 2009; Ansar et al., 
2007). These seemingly contradictory results may reflect intrinsic differences between in 
vitro and in vivo ?????????????????????????????????? ????????????????????????????????-
reducing effects were derived from in vitro studies lacking the proper neuroglial 
microenvironment and the systemic metabolism of in vivo drug administration. We 
?????????????????????????????????????????????????????????????????????????????????????????
moderate induction of stress responsive proteins (iHsp70 and Hsp40) by this drug 
(Figure 4-2 and Figure 4-4). It has been acknowledged that high levels of iHsp70 (and 
perhaps other co-???????????????????????????????????????????????????????????????????
degradation (Magrané et al., 2004), for example, Hsp70 overexpression in AD mice 
crossed with an Hsp70 transgenic (Hoshino et al., 2011; Bobkova et al., 2014), Hsp70 
overexpression in HD R6/2 mice crossed with Hsp70 overexpression mice (Hay et al., 
2004), and DNAJ (Hsp40) overexpression on Htt degradation in R6/2 mice (Labbadia et 
al., 2012). However, it appears that such high expression levels of chaperone proteins in 
animal models are ultimately unachievable via an Hsp90 inhibition approach. 
6.1.3 Novel Findings: HSF1-mediated Mechanism on Synapses
Based on previously published works, most of the investigations of Hsp90 
inhibitors on AD were focused on the co-chaperone functions of Hsp90, in which Hsp90 
inhibitors lead to disassociation of Hsp90 and its client proteins. Upon release from the 
Hsp90 complex, these client proteins could be degraded through the UPS. Previous 
studies in yeast, drosophila, and mammalian cells revealed that HSF1 is not only in 
charge of encoding genes of chaperone proteins under stressed conditions, such as heat 
shock, oxidative stress, heavy metal etc., but also its expression is involved in several 
important cellular events including signal transduction, protein degradation, ion 
transportation, energy production, carbonhydrate metabolism, vesicular transportation 
and cytoskeleton formation (Gonsalves et al., 2011; Hahn et al., 2004; Trinklein et al., 
2004). HSF1 is the major isoform that has been linked to chaperone protein dependent 
mechanisms of treating neurodegenerative diseases. 
Current studies have identified that HSF1 plays a pivotal role in not only 
regulation of the traditional heat shock response, but also regulation of synaptic activity 
and functions. OS47720 testing will certainly help clarify the previously unexamined role 
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of HSF-1 mediated synaptic regulation. From a biochemical perspective, HSF1 
overexpression significantly enhanced the synaptic protein PSD95. It should be noted that 
BDNF was also greatly upregulated. Meanwhile, downregulation of HSF1 by either the 
pharmacological inhibitor KRIBB11 or by AAVshRNAhsf1 abolished OS47720’s effect 
on synaptic proteins and BDNF. These results lead to the conclusion that HSF1 regulates 
synaptic activity and function, and that HSF1 is required for effective OS47720 activity 
on synapses. 
Our work demonstrates for the first time that OS47720, as a novel CNS-
permeable Hsp90 inhibitor, has the potential to be an effective therapeutic for the AD 
mouse model Tg-2576, by repairing synaptic structure, reestablishing neuronal contact 
and rescuing impaired memory, via an HSF1-mediated regulation. 
6.1.4 Transcriptional Regulation by HSF1: Potentially Another Master 
Transcriptional Factor for Memory
Pharmaceutical companies are currently investing in research for “Memory pills”, 
which are designed not only to rescue severe memory deficits caused by brain dementia 
like AD, but also to be used as a regular treatment for memory ailments in elders with 
mild memory loss, or for those who just want to prevent memory decline. For this 
purpose, Drs. Gary Lynch and Gary Rogers came up with the idea of boosting 
neurotransmitter (glutamate) signaling. Repeated glutamate exposure activates AMPA 
receptors, and triggers NMDA receptor activation, allowing a calcium influx. Receptor 
activation induces synaptic change, which is what is believed to be the basis of memory 
encoding and consolidation (Lynch, 2002; Lynch et al., 2011). The influential idea that 
cAMP and CREB regulated memory formation was formulated by the 2000 Nobel Prize 
winner Dr. Eric Kandel and his rival scientist Dr. Tim Tully. cAMP can induce a large 
pool of proteins that strengthen neuronal connections. Most importantly, cAMP activates 
CREB which triggers transcription of several genes involved in memory processes 
(Barco et al., 2003; Jackson et al., 2003; Tully et al., 2003). Drugs boosting cAMP/CREB 
or preventing breakdown of cAMP are currently under investigation and are in clinical 
trials (Alberini et al., 2014). In this study, 17-AAG increased phosphor-CREB (ser133) 
and BDNF in cultured models and mouse brain, indicating a possible 
HSF1/cAMP/CREB/BDNF signaling pathway. Hsp90 inhibition of induced 
cAMP/CREB activation may present another potential target for memory improvement 
(Figure 6-1).
In addition to heat shock response and its induced heat shock proteins, this work 
looks to highlight HSF1-mediated transcriptional upregulation of multiple synaptic genes, 
including genes coding for synapsin I, synaptophysin, PSD95 and BDNF. We have also 
identified that HSF1 is capable of inducing several immediate early genes (IEGs), 
including Arc, c-Fos, early growth response protein 1 (Egr1), early growth response 
protein 2 (Egr2), early growth response protein 3 (Egr3), and early growth response 
protein 4 (Egr4), etc. 
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Figure 6-1 Schematic Illustration of HSF1-mediated Mechanism.
The cartoon illustrates how an Hsp90 inhibitor activates HSF1, ultimately leading to gene 
transcriptional activation of both neuronal HSPs and synaptic proteins.  HSF1-mediated
genes play major roles both in heat shock-like stress response (HSR) and in synaptic 
regulation. It is well-accepted that local translation machinery is required for learning and 
memory in dendrites.  Despite a decade-long effort, there is still little known regarding 
the identity of the RNA molecules that are transported from the neuronal cell body 
(nucleus) to the synapse. Given the notion that heat shock responsive element (HSEs) are 
present in the promoters of several pre- and post-synaptic genes (syn I/synapsin I, 
Dlg4/PSD95, bdnf/BDNF, etc.), we speculate that HSF1 activation is required for the 
expression of these genes.  Because the mRNAs of these genes are known to be 
transported to synapses and protein translated locally in dendrites, we therefore believe 
that HSF1 regulates a functional synaptic transcriptome.  Activated CREB-P is known to 
be involved in this process. Both HSEs and CREs are present in many of the bdnf gene 
promoters, with some sites being close in vicinity or even overlapping. Therefore, HSF1 
and CREB may interact in regulating expression.
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Analysis of mRNA transcription was conducted by co-workers in Dr. Liao’s lab. 
Mice received foot shocks at an intensity of 0.7mA twice per 1 min interval. 1 h, 4h and 6 
h time points were chosen post-foot shock to examine the transcriptional activity. Two 
brain regions, hippocampal CA1 and amygdala were collected for gene profiling analysis. 
Immunofluorescence staining revealed a rapid increase of nuclear HSF1 in hippocampal 
CA1 pyramidal neurons within the first hour and the activity was sustained for at least 6 
hours. Immunofluorescence signal weakened at the 6 h time point, especially in 
comparison to the 1 h and 4 h time points. qRT-PCR demonstrated simultaneous 
upregulation of c-fos and Arc in hippocampal CA1 and, to a lesser degree, in the 
amygdala, and both peaked at 1 h post-foot shock training in mice. This was consistent 
with the increase of nuclear HSF1 post-foot shock exhibited in immunofluorescence 
staining. Different BDNF exon isoforms were also discovered to be elevated after foot 
shock, specifically the activity dependent exon I, and to a lesser extent exons IV and V 
(Lubin et al., 2012).  
Consistent with foot shock stress, Hsp90 inhibition yielded similar results. Hsp90 
inhibition was achieved by systemic administrating of OS47720 in mice. A complete 
gene profiling was conducted using a commercially available synaptic plasticity PCR 
array kit (Qiagen, Inc.). Array data confirmed the increase of Arc, c-Fos, and the 
important Dlg4 (coding gene for PSD95) upon OS47720 treatment. Several IEGs were 
also significantly upregulated, including Egr1, Egr2, Egr3, Egr4. A full gene profiling 
analysis revealed genomic transcriptional regulation of HSF1.
Structurally, based on the consensus sequences of HSF1-binding elements (HSEs), 
our work identified potential HSEs in the promoter regions of these genes. Among them, 
we provide evidence of direct binding of HSF1 to an HSE1 site in close proximity to the 
key CREB binding site (CRE) in bdnf promoter I, which was upregulated 1 h post-foot 
shock. Additionally, several IEGs were also induced at this time point. This result implies 
that HSF1 is another principle transcriptional factor required for gene upregulation during 
consolidation or retention of fear contextual conditioned freezing memory. This concept 
was also supported by the data demonstrating significant abrogating effects of the HSF1 
inhibitor administered 1 h post-training (Figure 5-7).  
The HSF1 regulated transcriptome was reported in some cases to be impaired 
during neurodegeneration. Indeed, Prahlad and Morimoto found that repressed HSF1 
regulated transcriptional levels of heat shock proteins in neurodegenerative disease 
models in C. elegans (Prahlad and Morimoto, 2009). The HSF1-regulated transcriptome 
was also found to be blunted by an aggregated huntingtin (Htt) protein, which may 
participate in the neurodegeneration observed in HD (Riva et al., 2012). 
Therefore, based on the findings from the current study together with findings 
from other labmates, we hypothesize that HSF1 plays a regulatory role in reshaping the 
synaptic transcriptome on a genomic level that ultimately contributes to 
neurodegeneration and potentially represents another master transcriptional factor for 
memory (Figure 6-1). In order to examine this hypothesis, systemic biological 
approaches such as ChIP-sequencing will be utilized to compare CREB and HSF1 on 
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identifying the similarities of DNA binding sites. We predict that CREB and HSF1, both 
pertinent to synaptic functions, will have significant overlapping targeting genes. 
6.1.5 Neuronal Structure: Dendritic Spines
Axons, dendrites and dendritic spines comprise the active neuronal network. A 
typical dendritic spine has a spine head and a spine neck that connect the head of the 
spine and the shaft of the dendrite. Dendritic spines are variable and “plastic” which 
allows them to maintain dynamic homeostasis. Dendritic spines with synapses undergo 
rapid and broad changes in number, size, and shape within the neuronal network. 
Approximate 10-20% of spines can spontaneously form and be eliminated within hours. 
Due to the dynamic nature of the actin cytoskeleton in spines, most of the spines change 
their shape within seconds to several minutes. Spine dynamics are mostly activity-
dependent and BDNF is believed to be a key determinant in the levels of spines. In 
neuropsychiatric disorders, such as autism spectrum disorders (ASD), schizophrenia and 
AD, abnormalities in dendritic spines, particularly the largely reduced number and ratio 
of immaturity of spines, may be the original insult that initiates the pathologic cascade 
(Penzes et al., 2011). 
The close relation between structural dynamics of dendritic spines and cognitive 
memory has been extensively studied (Segal et al., 2005; Kasai et al., 2010). Increased 
spine formation and the enlargement of the spine head are believed to promote spatial 
learning and working memory (Mahmmound et al., 2015). It is not surprising since 
dendritic spines are the structural basis for functional activity. Thus, dynamic dendritic 
spines serve as a common substrate for neurodegenerative diseases with cognitive 
impairment. 
The development of the two-photon excitation confocal microscopy greatly 
facilitates the study of the dynamics of dendritic spines and their correlation with 
functional outcomes, such as behaviors. By using it, high resolution imaging in living 
tissue becomes feasible. Transcranial two-photon microscopy was further developed for 
long-term imaging and tracing each individual dendritic spine in living animals 
(Grutzendler et al., 2002). 
In the current study, through collaboration we also examined the dynamics of 
dendritic spines (spine formation and elimination) in young transgenic mice (postnatal 
30-32 days) that express yellow fluorescent protein (YFP) in pyramidal neurons in 
specific cortical layer V region, before and after OS47720 treatment. We observed 
prominently enhanced spine formation 24-48 h (~13% of increase) in cortical layer V 
following a single injection of OS47720 (100 mg/kg). The percentage of spine 
elimination was not changed. Although the hippocampal region would be a more ideal 
setting to investigate, it is unfeasible to get the probe to that deep area. Further 
investigation on spine formation will be necessary for Alzheimer’s mouse models after 
chronic OS47720 treatment.
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6.1.6 Neuronal Network Activity
Neuronal network activity has long been recognized as the fundamental basis for 
all memory processes, including formation, storage, maintenance, and retrieval. Long-
Term Potentiation (LTP) and Long-Term Depression (LTD) are among the most 
important neuronal events in spatial learning and memory observed in the hippocampus. 
The study on LTP began as early as the 1970s, where it was first discovered that rabbit 
hippocampus, when subjected to short high-frequency electrical stimulation (HFS) (for 
example, a few seconds), could enhance synaptic transmission for several days to weeks. 
The mechanism of LTP was studied due to the discovery of the unique properties of 
NMDA receptors primarily found in cultured hippocampal slices. NMDA receptor 
antagonists blocked the occurrence of LTP induced by HFS, but did not affect synaptic 
transmission induced by low-frequency stimulation. The calcium influx caused by the 
opening of NMDA channels by glutamate binding triggered LTP (Purves et al., 2001). 
Enhanced LTP is therefore believed to promote hippocampus-dependent learning and 
memory.
We examined the change of LTP in hippocampus after the treatment of 17-AAG
on rat cultured brain slices. In this study, LTP in the DG region, instead of commonly 
investigated CA1-CA3 regions, was measured. The rationale of doing this was that 
synaptic plasticity in the DG region was severely impaired, while synaptic plasticity in 
the CA1 region was relatively spared in several FAD mouse models. A single 
administration of 17-AAG was given 30 min before the high-frequency stimulation 
(HFS). Significantly enhanced LTP recorded from the granule neuron synapses at rat 
medial perforant path-dentate gyrus (called perforant pathway) was observed. Both the 
amplitude of population spikes (PS) and the slope of excitatory postsynaptic potentials 
(EPSP) were significantly elevated after the treatment. On the other hand there were no 
obvious changes in basal levels of synaptic transmission without HFS was observed. 
When 17-AAG was given 30 min after the HFS, no change was found in either the 
amplitude of PS or the slope of EPSP. Therefore, the effect of 17-AAG is likely to be 
effective on the induction phase, but not the maintenance phase of hippocampal LTP 
(Chen et al., 2014).
Memory processes are based on neuronal communication and plasticity. Local 
field potential (LFP) indicates the neuronal network state and accounts for the neuronal 
activity response (Kelly et al., 2010). By computing the coherence, we can evaluate the 
correlation of local field potentials between two recording sites in different brain regions. 
Enhanced coherence, particularly in the low frequency oscillation (theta phase 
synchronization at 4-8 Hz for example), in the hippocampus (CA1 and CA3) was 
observed during the tasks involving working memory, while the coherence, in the delta 
(0.5-3 Hz), theta (4-????????????-30 Hz) and gamma (30-100 Hz) phases were enhanced 
between pre-frontal cortex and the hippocampus during the tasks involving long-term 
memory (Montgomery et al., 2007).  These new findings implied that both working 
memory and long-term memory could be supported by coherence enhancement (phase 
synchronization), since these two forms of memories were traditionally considered 
separate systems.
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In the in vivo electrophysiology study of aged mice (18 months), OS47720 was 
found to mediate its effect via highly novel synaptic strengthening mechanisms via 
modulation of Hsp90. The unique sustained (> 3 d) induction of synaptic genes/protein 
expression after a single i.p. injection of OS47720 may be attributed to multiple 
mechanisms, including transcriptional regulation. This was not surprising given the large 
pool (> 800) of cellular proteins identified as Hsp90 client proteins, many of which may 
include membrane receptors necessary for neuronal transmission (e.g., AMPAR) (Gerges 
et al., 2004), as well as proteins regulating post-transcriptional microRNAs and 
translational processes. 
In the current study, we demonstrated that, in healthy aged mice (18 months), 
OS47720 alters coherence of LFP activity within the hippocampal CA1 region and 
????????????????????????????????????????????????- 30Hz), gamma (30 - 100Hz) and 
higher frequency (190 - 200 Hz) oscillations. Coherence measures the degree of phase-
locking of oscillatory neuronal activity between the two recording sites. Coherence is an 
indicator of neuronal communication between brain structures that has been implicated in 
several cognitive processes (Bastos et al., 2015; Buzsaki and Schomburg, 2015; Fries et 
al., 2015). Abnormalities in coherence (reduced) of brain activity have been shown to be 
associated with AD, both in humans (Chen et al., 2013; Hsiao et al., 2013) and in mouse 
models (Liu et al., 2013) of the disease. It has been proposed that measures of coherence 
of brain activity could serve as a biomarker for AD (Sankari et al., 2012; Basar et al., 
2013). LFP coherence between the PFC and CA1 within the gamma frequency range has 
been strongly implicated in attention, working memory and memory consolidation 
(Spellman et al., 2015; Benchenane et al., 2011). Our findings suggest that the rescue of 
memory deficits by OS47720 treatment observed in AD mice is indicative of OS47720 
affecting coherent neuronal activity within hippocampus, and between the PFC and CA1.
6.1.7 Impaired HSF1 and Dysregulation in Neurodegeneration
HSF1 dysregulation in neurodegeneration remains largely understudied. There 
was a recently published report claiming dysregulation of heat shock protein under 
conditions of pathological TDP-43 aggregation (ALS associated gene). In their research, 
Chang HY et al. found that 17-AAG reduced the aggregation levels of pathological 
misfolded TDP-43 protein by normalizing heat shock proteins, mainly HSF1, Hsp70 and 
Hsp27; however it was left unaddressed exactly how heat shock proteins had been 
dysregulated in in vitro cell culture model under those pathological conditions (Chang et 
al., 2013). Protein expression levels of HSF1 were significantly reduced in the granule 
Purkinje neurons in AD rat cerebellum. Protein overexpression by AAV-delivered HSF1 
into the brain stem reversed neurodegeneration (Jiang et al., 2013). 
For this study in aged Tg2576 mice, in both 3 months and 6 months treatment 
cohorts, we surprisingly found significantly reduced (~ 20 %) protein expression of HSF1 
in the hippocampi relative to their Non-Tg littermates (Figure 4-10 and Figure 4-12). 
Chronic OS47720 treatment not only rescued reduced HSF1 expression, but also elevated 
basal levels of expression in Non-Tg mice. We have evidence supporting the role of an 
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Hsp90 inhibitor upregulating the hsf1 gene in neurons. The idea that a specific Hsp90 
inhibitor can upregulate the HSF1 gene and regulate protein expression has not yet been 
reported proven. 
According to our study, althou??????????????????????????????????????????????????
neuronal cellular cultures, as well as in APP-overexpressing FAD transgenic mice, the 
extent of HSF1 loss is not as severe as in cases of ALS, alpha-synuclein, or R6/2 Htt 
transgenic mice. This implied the existing common fact of HSF1 dysregulation and also 
different pathologies of each individual disease. Recently, other members from Dr. Liao’s 
????????????????????????????-synuclein overexpression lead to ubiquitination and further 
degradation of HSF1 via the ubiquitin proteasome system (UPS). This process is strictly 
mediated by the E3 ubiquitin-protein ligase NEDD4 also known as neural precursor cell 
expressed developmentally down-regulated protein 4 (NEDD4). Reduced NEDD4 or 
increased HSF1 via biochemical ????????????????????????????????????????????????-
synuclein induced toxicity. In vivo studies confirmed and revealed loss of HSF1 protein 
due to UPS-mediated protein degradation in patient brains with Lewy’s bodies. This was 
caused by proteotoxic stresses ????? ??????????????????????????????????????????-
????????????????? ??????????????????-synucleinopathy (Kim et al., 2015).  
As a master transcriptional regulator in all mammalian cells, loss of HSF1 can 
cause many cellular and subcellular consequences, most of which would be harmful. As a 
result, HSF1-mediated heat shock response and stress response will be compromised. 
This will greatly impact the disease onset, development and progression during 
pathological neurodegeneration. Moreover, as an integrated part for keeping proteasomal 
homeostasis, even partial loss of HSF1 could lead to detrimental effect on protein 
degradation machinery system. Given the fact that, in our study HSF1 can not only 
masterly regulates its classic heat shock and stress responses, but also regulates a couple 
of genes associated with synaptic functions, such as bdnf, partial loss of HSF1 was found 
to significantly damage synaptic functions and its causal behavior outcomes (locomotor 
activity, object recognition memory, etc.) (Figure 5-5). Therefore due to the multi-
functional role of HSF1, HSF1 dysregulation may represent a common and fundamental 
mechanism of neurodegenerative disease. It should be noted that the reduction of HSF1 
caused by UPS degradation appeared to be induced only by proteotoxic stress, and not by 
heat stress, per our recent study. Hsp90 inhibitors induced HSF1 activation that may 
correct and normalize the dysregulated function of HSF1 and its mediated heat shock-like 
response and synaptic functions. 
6.1.8 Therapeutic Implication of OS47720 in AD
Although HSF1 is well known as the most important master heat shock and stress 
response regulator, its role and regulatory mechanism in CNS disease remains unclear. 
This restudy was carried out to address this void in understanding, its role in 
neurodegenerative diseases. Upon investigating this Hsp90 inhibitor OS47720, we 
believe that pharmacological agents can activate and stabilize HSF1 protein expression 
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and function with therapeutic promise in treating chronic neurodegenerative diseases, 
such as AD.  
It has been over two decades since the concept of targeting Hsp90 first arose. 
Hsp90 has been validated in regulating several tumor suppressor pathways. Successful 
application of Hsp90 inhibition in various cancers in both preclinical and clinical studies 
will greatly support the on-going development of those agents. On the other hand, it has
been approximate 10 years since the idea of using Hsp90 inhibitors in treating 
neurodegenerative diseases was first introduced. While there were several Hsp90 
inhibitors exhibiting neuroprotection potential in in vitro models of many diseases, 
limited success was achieved with in vivo activity. Compared with the four currently-
known CNS-permeable Hsp90 inhibitors (Dickey et al., 2007; Labbadia et al., 2011; Cha 
et al., 2014; Luo et al., 2007), which had in vivo testing in models of neurodegenerative 
diseases (Table 6-1), OS47720 is the only Hsp90 inhibitor compound that has 
demonstrated superb in vivo therapeutic performance, including an apparent lack of 
systemic toxicity at therapeutically-relevant dosage over a chronic period of time (3 
months in presymptomatic mice and 6 months in middle symptomatic mice). There is no 
follow-up study for those four compounds, with possible reasons including long-term 
toxicity, lack of in vivo therapeutic efficacy, or the pathological differences among 
neurodegenerative diseases.
Currently there is limited success treating AD with CNS-permeable compounds. 
This leads us to consider a potential fundamental difference between AD and other 
neurodegenerative diseases (PD, HD, ALS, etc.). It appears that AD is more of a synaptic 
disease (Palop and Muche, 2010; Koffie et al., 2011), characterized by a slow and 
progressive deterioration, in comparison to those diseases caused by severe proteinopathy, 
which is more rapidly developed. The idea of applying Hsp90 inhibitors to AD becomes 
more attractive and promising when considering the twenty to thirty year window of 
chronic neurodegeneration in AD compared to a less than 2 year disease onset in ALS. 
Our work firstly presents a pharmacologically feasible Hsp90 inhibitor (OS47720) by
demonstrating the feasibility of treating a chronic dysfunctional synaptic disease such as 
AD. Most notably, it is effective in treating early and middle symptomatic mice with 
amyloid plaque load via HSF1 mediated synaptic protection mechanism. 
6.2 Conclusions
In this research, we used various biochemical and behavioral approaches to study 
Hsp90 inhibitors feasibility in AD treatment. Through the investigation of a 
commercially available Hsp90 inhibitor, 17-AAG, we proved that targeting Hsp90 
inhibi???????????????????????????????????-induced toxicity, in both an in vitro cell culture 
model and an in vivo ????????? ????? ???????????????????????????????????????????????????
heat shock and stress responses, HSF1 efficacy in regulation of synaptic genes and
functions ultimately championed clinical application. The novel compound OS47720 
overcomes the two major developmental hurdles for Hsp90 inhibitors: systemic toxicity 
and limited CNS permeability. No noticeable systemic toxicity was observed based on 
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body weight and daily activity monitoring during the chronic 3 months and 6 months 
treatment in two different Tg2576 mice cohorts, suggesting a feasible safety profile. A 
single intraperitoneal injection of OS47720 at 100 mg/kg dosage induced rapid 
compound accumulation in the brain within 1 h, and was gradually cleared by 24 h. 
Despite a short half-life of OS47720 in mouse brain, a single systemic injection induces 
rapid and long-lasting (> 3 d) nuclear activation of HSF1, suggesting good CNS 
permeability. We then demonstrated that chronic treatment with this proprietary 
compound OS47720 not only elicited a heat shock-like response, but also provided 
synaptic protection in early and middle symptomatic Tg2576 mice, a mouse model of 
Alzheimer’s disease (AD), as evidenced by various behavioral and biochemical tests. 
Mechanistic studies indicated that the therapeutic effects of OS47720 depended upon 
HSF1 activation and the subsequent HSF1-mediated transcriptional events on synaptic 
genes. Hence, this work demonstrates promising translational significance. Taken 
together, this work reveals not only that the Hsp90 inhibitor OS47720 holds therapeutic 
promise in treating AD, but also identifies that HSF1 plays an instrumental role in 
synaptic function and memory by way of synaptic transcriptome modulation.
6.3 Future Directions
Hsp90 inhibitors have been recognized as promising agents in treating various 
types of cancers for over two decades. Previous and current studies (Dickey et al., 2007; 
Labbadia et al., 2011; Cha et al., 2014; Luo et al., 2007) have brought neurodegenerative 
diseases to the forefront of diseases that Hsp90 inhibitors can potentially treat. Our work 
validated the feasibility of using one type of Hsp90 inhibitor - OS47720 in treating AD 
characterized by synaptic dysfunction. There was only a single AD mouse model used in 
this study, thus it will be necessary to test OS47720 in additional AD mouse models, 
including APP models (J20, 5×FAD, etc.) and tau models (PS19, rTg4510, etc.), for its in 
vivo efficacy. Tau pathology represents the other molecular hallmark of AD. 
In our current study, post-mortem tests revealed that OS47720 demonstrated a 
???????????????????????????????????????????????????????????????????????????????????????
????????????????????? been well characterized for its cellular toxicity, it may be worth 
investigating as a target, perhaps being treated with a combination of an Hsp90 inhibitor 
and some form of anti-??????????????????????????-secretase inhibitors). This may 
ultimately offer a viable treatment paradigm for treating symptomatic AD patients.  
Currently there are three “viable” Hsp90 inhibition compounds that are actively 
being tested for their potential in vivo efficacy in treating neurodegenerative diseases. 
Among them, The NVP series compounds from Novartis Oncology company exhibits the 
greatest efficacy with regard to Hsp90 inhibition, with IC50 NVP-Hsp990= 0.6 nM and 
IC50NVP-AUY922= 13 nM. These compounds are commercially available. The AU 
series compounds are synthesized at Dr. Chiosis’s laboratory from Memorial Sloan–
Kettering Cancer Center. The leading compounds PU-H71 and PU-DZ8 have modest 
potency on Hsp90 inhibition, with IC50PU-H71= 80 nM and IC50PU-DZ8 = 160 nM 
(Taldone et al., 2010). Similarly, OS47720 displays an IC50 value at around a hundred 
91
nanomolar level. Testing the more potent compound AUY922 becomes feasible in further 
addressing the hypothesis of targeting Hsp90 inhibition for treating AD through HSF1-
mediated regulation at synapses. So far, most of compound development has been 
focused on targeting the ATP binding pocket located in the N-terminus domain of Hsp90. 
The other C-terminus domain could be a potential secondary target site; however there is 
minimal research to justify this. Coumarin antibiotics, such as novobiocin, are the 
prototypic inhibitors targeting this site which still requires future work. 
Although significant progress has been made in current study, many important 
questions remain unanswered. This project has demonstrated that the OS47720 
compound represents a useful pharmacological inducer of heat shock response, and 
further serves as a promoter of synaptic activity with prospective in vivo application.
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